Document:

Exhibit 4.6

 

Registration
Rights Agreement

 

This Registration Rights
Agreement (this “Agreement”) is made and entered into effective as of April 11, 2014 (the “Effective
Date”) between Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and
the persons who have executed the signature page(s) hereto (each, a “Purchaser” and collectively, the “Purchasers”).

 

RECITALS:

 

WHEREAS, the Company
has entered into an Agreement and Plan of Merger with JB Therapeutics Inc., a Delaware corporation (“JB Therapeutics”),
pursuant to which a newly organized, wholly-owned subsidiary of the Company has merged with and into JB Therapeutics, with JB Therapeutics
remaining as the surviving entity and a wholly-owned subsidiary of the Company (the “Merger”);

 

WHEREAS, simultaneously
with the Merger and to provide the capital required by the Company for working capital and other purposes, the Company has offered
in compliance with Rule 506(b) of Regulation D and/or Regulation S of the Securities Act (as defined herein), to investors in a
private placement transaction (the “PPO”), units (“Units”) of its securities, each Unit consisting
of Two Hundred Fifty Thousand (250,000) shares of Common Stock (the “Investor Shares”) and Two Hundred Fifty
Thousand (250,000) warrants (the “Investor Warrants”) to purchase Two Hundred Fifty Thousand (250,000) shares
of Common Stock;

 

WHEREAS, the initial
closing of the PPO and the closing of the Merger have taken place on the Effective Date;

 

WHEREAS, in connection
with the Merger and the PPO, the Company agreed to provide certain registration rights related to the Investor Shares and the shares
of Common Stock issuable upon exercise of the Investor Warrants, on the terms set forth herein;

 

WHEREAS, in connection
with the Merger and the PPO, the Company agreed to issue (i) warrants to purchase 917,612 shares of Common Stock of the Company
(the “Merger Warrants”) to the preferred stockholders of JB Therapeutics (“JBT Preferred Holders”)
along with certain registration rights related to the shares of Common Stock issuable upon exercise of the Merger Warrants and
(ii) warrants to purchase an aggregate of 329,617 shares of Common Stock of the Company (the “Replacement Warrants”
and collectively, with the Merger Warrants, the “JBT Holder Warrants”) to the warrant holders of JB Therapeutics
(“JBT Warrant Holders” and collectively, with the JB Preferred Holders, the “JBT Holders”)
along with certain registration rights related to the shares of Common Stock issuable upon exercise of the Replacement Warrants;

 

Now,
Therefore, in consideration of the mutual promises, representations, warranties, covenants, and conditions set forth herein,
the parties mutually agree as follows:

 

1.          Certain
Definitions. As used in this Agreement, the following terms shall have the following respective meanings:

 

    	 

    	 

    

 

“Approved
Market” means the Over-the-Counter Bulletin Board, the OTC Markets, the Nasdaq Stock Market, the New York Stock Exchange
or the NYSE MKT.

 

“Blackout
Period” means, with respect to a registration, a period, in each case commencing on the day immediately after the Company
notifies the Purchasers that they are required, because of the occurrence of an event of the kind described in Section 4(f) hereof,
to suspend offers and sales of Registrable Securities during which the Company, in the good faith judgment of its board of directors,
determines (because of the existence of, or in anticipation of, any acquisition, financing activity, or other transaction involving
the Company, or the unavailability for reasons beyond the Company’s control of any required financial statements, disclosure
of information which is in its best interest not to publicly disclose, or any other event or condition of similar significance
to the Company) that the registration and distribution of the Registrable Securities to be covered by such Registration Statement,
if any, would be seriously detrimental to the Company and its stockholders and ending on the earlier of (1) the date upon which
the material non-public information commencing the Blackout Period is disclosed to the public or ceases to be material and (2)
such time as the Company notifies the selling Holders that the Company will no longer delay such filing of the Registration Statement,
recommence taking steps to make such Registration Statement effective, or allow sales pursuant to such Registration Statement to
resume.

 

“Business
Day” means any day of the year, other than a Saturday, Sunday, or other day on which the Commission is required or authorized
to close.

 

“Commission”
means the U. S. Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

 

“Common Stock”
means the common stock, par value $0.0001 per share, of the Company and any and all shares of capital stock or other equity securities
of: (i) the Company which are added to or exchanged or substituted for the Common Stock by reason of the declaration of any stock
dividend or stock split, the issuance of any distribution or the reclassification, readjustment, recapitalization or other such
modification of the capital structure of the Company; and (ii) any other corporation, now or hereafter organized under the laws
of any state or other governmental authority, with which the Company is merged, which results from any consolidation or reorganization
to which the Company is a party, or to which is sold all or substantially all of the shares or assets of the Company, if immediately
after such merger, consolidation, reorganization or sale, the Company or the stockholders of the Company own equity securities
having in the aggregate more than 50% of the total voting power of such other corporation.

 

“Effective
Date” has the meaning given it in the preamble to this Agreement.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder.

 

    	 

    	 

    

 

“Family Member”
means (a) with respect to any individual, such individual’s spouse, any descendants (whether natural or adopted), any trust
all of the beneficial interests of which are owned by any of such individuals or by any of such individuals together with any organization
described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, the estate of any such individual, and any corporation,
association, partnership or limited liability company all of the equity interests of which are owned by those above described individuals,
trusts or organizations and (b) with respect to any trust, the owners of the beneficial interests of such trust.

 

“Holder”
means each Purchaser (including, for purposes of this definition, each JBT Holder) or any of such Purchaser’s respective
successors and Permitted Assignees who acquire rights in accordance with this Agreement with respect to any Registrable Securities
directly or indirectly from a Purchaser or from any Permitted Assignee.

 

“Initial Registration
Statement” means the initial Registration Statement filed pursuant to this Agreement.

 

“Investor
Shares” has the meaning given it in the recitals of this Agreement.

 

“Investor
Warrants” has the meaning given it in the recitals of this Agreement.

 

“Majority
Holders” means at any time Holders representing a majority of the Registrable Securities.

 

“Merger Warrants”
has the meaning given in the recitals of this Agreement.

 

“JBT Holder
Warrants” has the meaning given in the recitals of this Agreement.

 

“JBT Holders”
has the meaning given in the recitals of this Agreement and such Holders are listed on Annex A hereto.

 

“Permitted
Assignee” means (a) with respect to a partnership, its partners or former partners in accordance with their partnership
interests, (b) with respect to a corporation, its stockholders in accordance with their interest in the corporation, (c) with respect
to a limited liability company, its members or former members in accordance with their interest in the limited liability company,
(d) with respect to an individual party, any Family Member of such party, (e) an entity that is controlled by, controls, or is
under common control with a transferor, or (f) a party to this Agreement.

 

“Piggyback
Registration” means, in any registration of Common Stock as set forth in Section 3(b), the ability of holders of Registrable
Securities to include Registrable Securities in such registration.

 

“Redemption
Notice” has the meaning given it in Section 3(f) of this Agreement.

 

The terms “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing
a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration
statement.

 

    	 

    	 

    

 

“Registrable
Securities” means the Investor Shares and the Registrable Warrant Shares but excluding, subject to Section 3(e), (i)
any Registrable Securities that have been publicly sold or may be sold immediately without registration under the Securities Act
either pursuant to Rule 144(k) of the Securities Act or otherwise; (ii) any Registrable Securities sold by a person in a transaction
pursuant to a registration statement filed under the Securities Act, or (iii) any Registrable Securities that are at the time subject
to an effective registration statement under the Securities Act.

 

“Registrable
Warrant Shares” means the shares of Common Stock issued or issuable to each Holder upon exercise of the Investor Warrants
and the JBT Holder Warrants, as the case may be.

 

“Registration
Default Date” means the date that is 150 days after the date the Registration Statement is actually filed with the Commission.

 

“Registration
Default Period” means the period following the Registration Default Date during which any Registration Event occurs and
is continuing.

 

“Registration
Event” means the occurrence of any of the following events:

 

(a)          the
Company fails to file with the Commission the Registration Statement on or before the Registration Filing Date;

 

(b)          the
Registration Statement is not declared effective by the Commission on or before the Registration Default Date;

 

(c)          after
the SEC Effective Date, sales cannot be made pursuant to the Registration Statement for any reason (including without limitation
by reason of a stop order, or the Company’s failure to update the Registration Statement) except as excused pursuant to Section
3(e); or

 

(d)          the
Common Stock generally or the Registrable Securities specifically are not listed or included for quotation on an Approved Market,
or trading of the Common Stock is suspended or halted on the Approved Market, which at the time constitutes the principal market
for the Common Stock, for more than two full, consecutive Trading Days; provided, however, a Registration Event shall
not be deemed to occur if all or substantially all trading in equity securities (including the Common Stock) is suspended or halted
on the Approved Market for any length of time.

 

“Registration
Filing Date” means the date that is 60 days after date of the final closing of the PPO.

 

“Registration
Statement” means the registration statement that the Company is required to file pursuant to this Agreement to register
the Registrable Securities.

 

“Release Date”
has the meaning given it in Section 3(f) of this Agreement.

 

“Replacement
Warrants” has the meaning given in the recitals of this Agreement.

 

“Rule 144”
means Rule 144 promulgated by the Commission under the Securities Act.

 

    	 

    	 

    

 

“Rule 145”
means Rule 145 promulgated by the Commission under the Securities Act.

 

“Rule 415”
means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, or any similar federal statute promulgated in replacement thereof,
and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time.

 

“SEC Effective
Date” means the date the Registration Statement is declared effective by the Commission.

 

“Trading Day”
means (a) if the Common Stock is listed or quoted on an Approved Market, then any day during which securities are generally eligible
for trading on the Approved Market, or (b) if the Common Stock is not then listed or quoted and traded on an Approved Market, then
any business day.

 

“Transfer”
has the meaning given it in Section 3(f) of this Agreement.

 

2.            Term.
This Agreement shall continue in full force and effect for a period of one year from the SEC Effective Date, unless terminated
sooner hereunder.

 

3.            Registration.

 

(a)          Registration
on Form S-1. Not later than the Registration Filing Date, the Company shall file with the Commission a Registration Statement
on Form S-1, or other applicable form, relating to the resale by the Holders of all of the Registrable Securities, and the Company
shall use its commercially reasonably efforts to cause such Registration Statement to be declared effective prior to the Registration
Default Date.

 

(b)          Piggyback
Registration. In addition to the Company agreement pursuant to Section 3(a) above, if the Company shall determine to register
for sale for cash any of its Common Stock, for its own account or for the account of others (other than the Holders), other than
(i) a registration relating solely to employee benefit plans or securities issued or issuable to employees, consultants (to the
extent the securities owned or to be owned by such consultants could be registered on Form S-8) or any of their Family Members
(including a registration on Form S-8) or (ii) a registration relating solely to a Securities Act Rule 145 transaction or a registration
on Form S-4 in connection with a merger, acquisition, divestiture, reorganization or similar event, the Company shall promptly
give to the Holders written notice thereof (and in no event shall such notice be given less than 20 calendar days prior to the
filing of such registration statement), and shall, subject to Section 3(c), include as a Piggyback Registration all of the Registrable
Securities specified in a written request delivered by the Holder thereof within 10 calendar days after receipt of such written
notice from the Company. However, the Company may, without the consent of the Holders, withdraw such registration statement prior
to its becoming effective if the Company or such other stockholders have elected to abandon the proposal to register the securities
proposed to be registered thereby.

 

    	 

    	 

    

 

(c)          Underwriting.
If a Piggyback Registration is for a registered public offering that is to be made by an underwriting, the Company shall so advise
the Holders of the Registrable Securities eligible for inclusion in such Registration Statement pursuant to Sections 3(b). In that
event, the right of any Holder to Piggyback Registration shall be conditioned upon such Holder’s participation in such underwriting
and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders
proposing to sell any of their Registrable Securities through such underwriting shall (together with the Company and any other
stockholders of the Company selling their securities through such underwriting) enter into an underwriting agreement in customary
form with the underwriter selected for such underwriting by the Company or the selling stockholders, as applicable. Notwithstanding
any other provision of this Section, if the underwriter or the Company determines that marketing factors require a limitation on
the number of shares of Common Stock or the amount of other securities to be underwritten, the underwriter may exclude some or
all Registrable Securities from such registration and underwriting. The Company shall so advise all Holders (except those Holders
who failed to timely elect to include their Registrable Securities through such underwriting or have indicated to the Company their
decision not to do so), and indicate to each such Holder the number of shares of Registrable Securities that may be included in
the registration and underwriting, if any. The number of shares of Registrable Securities to be included in such registration and
underwriting shall be allocated among such Holders as follows:

 

(i)          If
the Piggyback Registration was initiated by the Company, the number of shares that may be included in the registration and underwriting
shall be allocated first to the Company and then, subject to obligations and commitments existing as of the date hereof, to all
selling stockholders, including the Holders, who have requested to sell in the registration on a pro rata basis according to the
number of shares requested to be included therein; and

 

(ii)         If
the Piggyback Registration was initiated by the exercise of demand registration rights by a stockholder or stockholders of the
Company (other than the Holders), then the number of shares that may be included in the registration and underwriting shall be
allocated first to such selling stockholders who exercised such demand and then, subject to obligations and commitments existing
as of the date hereof, to all other selling stockholders, including the Holders, who have requested to sell in the registration
on a pro rata basis according to the number of shares requested to be included therein.

 

No Registrable Securities
excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration
and no liquidated damages as set forth in Section 3(d) shall accrue with respect to such excluded securities. If any Holder disapproves
of the terms of any such underwriting, such Holder may elect to withdraw such Holder’s Registrable Securities therefrom by
delivering a written notice to the Company and the underwriter. The Registrable Securities so withdrawn from such underwriting
shall also be withdrawn from such registration; provided, however, that, if by the withdrawal of such Registrable
Securities, a greater number of Registrable Securities held by other Holders may be included in such registration (up to the maximum
of any limitation imposed by the underwriters), then the Company shall offer to all Holders who have included Registrable Securities
in the registration the right to include additional Registrable Securities pursuant to the terms and limitations set forth herein
in the same proportion used above in determining the underwriter limitation.

 

    	 

    	 

    

 

(d)          Occurrence
of Registration Event. If a Registration Event occurs, then the Company will make payments to each Holder of Registrable Securities
(a “Qualified Purchaser”), as liquidated damages for the amount of damages to the Qualified Purchaser by reason
thereof, at a rate equal to 0.50% of the purchase price per Unit paid by such Holder in the PPO for the Registrable Securities
then held by each Qualified Purchaser for each full period of 30 days of the Registration Default Period (which shall be pro-rated
for any period less than 30 days); provided, however, if a Registration Event occurs (or is continuing), liquidated
damages shall be paid only with respect to that portion of the Qualified Purchaser’s Registrable Securities that cannot then
be immediately resold in reliance on Rule 144. Notwithstanding the foregoing, the maximum amount of liquidated damages that may
be paid to any Qualified Purchaser pursuant to this Section 3(d) shall be an amount equal to 6% of the purchase price per Unit
paid by such Holder in the PPO for the Registrable Securities held by such Qualified Purchaser at the time of the first occurrence
of a Registration Event. Each such payment shall be due and payable within five days after the end of each full 30-day period of
the Registration Default Period until the termination of the Registration Default Period and within five days after such termination.
Such payments shall constitute the Qualified Purchaser’s exclusive remedy for such events. If the Company fails to pay any
partial liquidated damages or refund pursuant to this Section in full within seven days after the date payable, the Company will
pay interest thereon at a rate of 2% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to
the Holder, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon,
are paid in full. The Registration Default Period shall terminate upon (i) the filing of the Registration Statement in the case
of clause (a) of the definition of Registration Event, (ii) the SEC Effective Date in the case of clause (b) of the definition
of Registration Event, (iii) the ability of the Qualified Purchaser to effect sales pursuant to the Registration Statement in the
case of clause (c) of the definition of Registration Event, and (iv) the listing or inclusion and/or trading of the Common Stock
on an Approved Market, as the case may be, in the case of clause (d) of the definition of Registration Event. The amounts payable
as liquidated damages pursuant to this Section 3(d) shall be payable in lawful money of the United States.

 

(e)          Notwithstanding
the provisions of Section 3(d) above:

 

(1)(a) if the Commission
does not declare the Registration Statement effective on or before the Registration Default Date, or (b) if the Commission allows
the Registration Statement to be declared effective at any time before or after the Registration Default Date, subject to the withdrawal
of certain Registrable Securities from the Registration Statement, and the reason for (a) or (b) is the Commission’s determination
that (x) the offering of any of the Registrable Securities constitutes a primary offering of securities by the Company, (y) Rule
415 may not be relied upon for the registration of the resale of any or all of the Registrable Securities, and/or (z) a Holder
of any Registrable Securities must be named as an underwriter, the Holders understand and agree that in the case of (b) the Company
may reduce, on a pro rata basis, the total number of Registrable Securities to be registered on behalf of each such Holder,
and, in the case of (a) or (b), that a Holder shall not be entitled to any liquidated damages with respect to the Registrable Securities
not registered for the reason set forth in (a), or so reduced on a pro rata basis as set forth in (b). In any such pro
rata reduction, the number of Registrable Securities to be registered on such Registration Statement will first be reduced
by (i) first, all of the Registrable Securities held by the JBT Holders, (ii) second, the Registrable Securities represented by
the Registrable Warrant Shares (applied, in the case that some Registrable Warrant Shares may be registered, to the Holders on
a pro rata basis based on the total number of unregistered Registrable Warrant Shares held by such Holders on a fully diluted
basis), and (iv) third, Registrable Securities represented by Investor Shares (applied, in the case that some Investor Shares may
be registered, to the Holders on a pro rata basis based on the total number of unregistered Investor Shares held by such
Holders). In addition, any such affected Holder shall be entitled to Piggyback Registration
rights after the Registration Statement is declared effective by the Commission until such time as: (AA) all Registrable Securities
have been registered pursuant to an effective Registration Statement, (BB) the Registrable Securities may be resold without restriction
pursuant to Rule 144 of the Securities Act, or (CC) the Holder agrees to be named as an underwriter in any such registration statement.
The Holders acknowledge and agree the provisions of this paragraph may apply to more than one Registration Statement; and

 

    	 

    	 

    

 

(2)         For
not more than thirty (30) consecutive days or for a total of not more than sixty (60) days in any twelve (12) month period, the
Company may suspend the use of any prospectus included in any Registration Statement contemplated by this Section in the event
that the Company determines in good faith that such suspension is necessary to (A) delay the disclosure of material non-public
information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the
best interests of the Company or (B) amend or supplement the affected Registration Statement or the related prospectus so that
such Registration Statement or prospectus shall not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of the circumstances
under which they were made, not misleading, including in connection with the filing of a post-effective amendment to such Registration
Statement in connection with the Company’s filing of an Annual Report on Form 10-K for any fiscal year (an “Allowed
Delay”); provided, that the Company shall promptly (a) notify each Holder in writing of the commencement of an Allowed Delay,
but shall not (without the prior written consent of an Holder) disclose to such Holder any material non-public information giving
rise to an Allowed Delay, (b) advise the Holders in writing to cease all sales under the Registration Statement until the end of
the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable.

 

In the event of an Allowed
Delay, the liquidated damages set forth in Section 3(d) shall not accrue during such Allowed Delay.

 

(f)          Holdback
Agreements. From and after the SEC Effective Date, each Holder understands that (i) it shall not sell, offer, pledge, contract
to sell, grant any option or contract to purchase, purchase any option or contract to sell, grant any right or warrant to purchase,
lend or otherwise transfer or encumber, directly or indirectly, any shares of the Registrable Securities (“Transfer”),
nor shall such Holder enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of any shares of the Registrable Securities until the Release Date (as defined below); provided
that such Holder shall be permitted to Transfer up to one-third of such Holder’s Registrable Securities held by it as of
the SEC Effective Date at any time on or after the SEC Effective Date, and (ii) following the Release Date, it shall be entitled
to sell the remaining Registrable Securities held by such Holder. Each Holder hereby covenants and agrees that (x) it shall abide
by the restrictions set forth above and (y) the Company shall be entitled to place “stop transfer” instructions with
the Company’s transfer agent in compliance with the above restrictions. For purposes of this clause (f), the term “Release
Date” shall mean six months from the SEC Effective Date; provided, that in the event the Company delivers a notice of
redemption to the Holders of the Investor Warrants (pursuant to the terms of the Investor Warrants) (the “Redemption Notice”),
the restrictions set forth above shall terminate effective on the date of delivery of the Redemption Notice.

 

    	 

    	 

    

 

4.            Registration
Procedures for Registrable Securities. The Company will keep each Holder reasonably advised as to the filing and effectiveness
of the Registration Statement. At its expense with respect to the Registration Statement, the Company will:

 

(a)          prepare
and file with the Commission with respect to the Registrable Securities, a Registration Statement on Form S-1, or any other form
for which the Company then qualifies or which counsel for the Company shall deem appropriate and which form shall be available
for the sale of the Registrable Securities in accordance with the intended methods of distribution thereof, and use its commercially
reasonable efforts to cause such Registration Statement to become effective and shall remain effective for a period of one year
or for such shorter period ending on the earlier to occur of (i) the date as of which all of the Holders as selling stockholders
thereunder may sell all of the Registrable Securities registered for resale thereon without restriction pursuant to Rule 144 (or
any successor rule thereto) promulgated under the Securities Act or (ii) the date when all of the Registrable Securities registered
thereunder shall have been sold (the “Effectiveness Period”). Thereafter, the Company shall be entitled
to withdraw such Registration Statement and the Purchasers shall have no further right to offer or sell any of the Registrable
Securities registered for resale thereon pursuant to the respective Registration Statement (or any prospectus relating thereto);

 

(b)          if
the Registration Statement is subject to review by the Commission, respond in a commercially reasonable manner to all comments
and diligently pursue resolution of any comments to the satisfaction of the Commission;

 

(c)          prepare
and file with the Commission such amendments and supplements to such Registration Statement as may be necessary to keep such Registration
Statement effective during the Effectiveness Period;

 

(d)          furnish,
without charge, to each Holder of Registrable Securities covered by such Registration Statement (i) a reasonable number of copies
of such Registration Statement (including any exhibits thereto other than exhibits incorporated by reference), each amendment and
supplement thereto as such Holder may reasonably request, (ii) such number of copies of the prospectus included in such Registration
Statement (including each preliminary prospectus and any other prospectus filed under Rule 424 of the Securities Act) as such Holders
may reasonably request, in conformity with the requirements of the Securities Act, and (iii) such other documents as such Holder
may require to consummate the disposition of the Registrable Securities owned by such Holder, but only during the Effectiveness
Period;

 

    	 

    	 

    

 

(e)          use
its commercially reasonable efforts to register or qualify such registration under such other applicable securities laws of such
jurisdictions as any Holder of Registrable Securities covered by such Registration Statement reasonably requests and as may be
necessary for the marketability of the Registrable Securities (such request to be made by the time the applicable Registration
Statement is deemed effective by the Commission) and do any and all other acts and things necessary to enable such Holder to consummate
the disposition in such jurisdictions of the Registrable Securities owned by such Holder; provided, that the Company shall
not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify
but for this paragraph, (ii) subject itself to taxation in any such jurisdiction, or (iii) consent to general service of process
in any such jurisdiction.

 

(f)          notify
each Holder of Registrable Securities, the disposition of which requires delivery of a prospectus relating thereto under the Securities
Act, of the happening of any event (as promptly as practicable after becoming aware of such event), which comes to the Company’s
attention, that will after the occurrence of such event cause the prospectus included in such Registration Statement, if not amended
or supplemented, to contain an untrue statement of a material fact or an omission to state a material fact required to be stated
therein or necessary to make the statements therein not misleading and the Company shall promptly thereafter prepare and furnish
to such Holder a supplement or amendment to such prospectus (or prepare and file appropriate reports under the Exchange Act) so
that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading, unless suspension of the use of such prospectus otherwise is authorized herein or in the event of a Blackout Period,
in which case no supplement or amendment need be furnished (or Exchange Act filing made) until the termination of such suspension
or Blackout Period;

 

(g)          comply,
and continue to comply during the Effectiveness Period, in all material respects with the Securities Act and the Exchange Act and
with all applicable rules and regulations of the Commission with respect to the disposition of all securities covered by such Registration
Statement;

 

(h)          as
promptly as practicable after becoming aware of such event, notify each Holder of Registrable Securities being offered or sold
pursuant to the Registration Statement of the issuance by the Commission of any stop order or other suspension of effectiveness
of the Registration Statement;

 

(i)          use
its commercially reasonable efforts to cause all the Registrable Securities covered by the Registration Statement to be quoted
on the OTC Bulletin Board or such other Approved Market on which securities of the same class or series issued by the Company are
then listed or traded;

 

(j)          provide
a transfer agent and registrar, which may be a single entity, for the shares of Common Stock at all times;

 

    	 

    	 

    

 

(k)          if
requested by the Holders, cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates shall be free,
to the extent permitted by applicable law, of all restrictive legends, and to enable such Registrable Securities to be in such
denominations and registered in such names as any such Holders may request;

 

(l)          during
the Effectiveness Period, refrain from bidding for or purchasing any Common Stock or any right to purchase Common Stock or attempting
to induce any person to purchase any such security or right if such bid, purchase or attempt would in any way limit the right of
the Holders to sell Registrable Securities by reason of the limitations set forth in Regulation M of the Exchange Act; and

 

(m)          take
all other reasonable actions necessary to expedite and facilitate the disposition by the Holders of the Registrable Securities
pursuant to the Registration Statement.

 

5.            Suspension
of Offers and Sales. Each Holder agrees that, upon receipt of any notice from the Company of the happening of any event of
the kind described in Section 4(f) hereof or of the commencement of a Blackout Period, such Holder shall discontinue the disposition
of Registrable Securities included in the Registration Statement until such Holder’s receipt of the copies of the supplemented
or amended prospectus contemplated by Section 4(f) hereof or notice of the end of the Blackout Period, and, if so directed by the
Company, such Holder shall deliver to the Company (at the Company’s expense) all copies (including, without limitation, any
and all drafts), other than permanent file copies, then in such Holder’s possession, of the prospectus covering such Registrable
Securities current at the time of receipt of such notice.

 

6.            Registration
Expenses. The Company shall pay all expenses in connection with any registration obligation provided herein, including, without
limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable
securities laws, and the fees and disbursements of counsel for the Company and of its independent accountants; provided,
that, in any registration, each party shall pay for its own underwriting discounts and commissions and transfer taxes. Except as
provided in this Section and Section 9, the Company shall not be responsible for the expenses of any attorney or other advisor
employed by a Holder.

 

7.            Assignment
of Rights. No Holder may assign its rights under this Agreement to any party without the prior written consent of the Company;
provided, however, that any Holder may assign its rights under this Agreement without such consent to a Permitted
Assignee as long as (a) such transfer or assignment is effected in accordance with applicable securities laws; (b) such transferee
or assignee agrees in writing to become subject to the terms of this Agreement; and (c) such Holder notifies the Company in writing
of such transfer or assignment, stating the name and address of the transferee or assignee and identifying the Registrable Securities
with respect to which such rights are being transferred or assigned.

 

8.            Information
by Holder. A Holder with Registrable Securities included in any registration shall furnish to the Company such information
regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be
required in order to comply with any applicable law or regulation in connection with the registration of such Holder’s Registrable
Securities or any qualification or compliance with respect to such Holder’s Registrable Securities and referred to in this
Agreement. A form of Selling Stockholder Questionnaire is attached as Exhibit B hereto for such purposes.

 

    	 

    	 

    

 

9.            Indemnification.

 

(a)          In
the event of the offer and sale of Registrable Securities under the Securities Act, the Company shall, and hereby does, indemnify
and hold harmless, to the fullest extent permitted by law, each Holder, its directors, officers, partners, each other person who
participates as an underwriter in the offering or sale of such securities, and each other person, if any, who controls or is under
common control with such Holder or any such underwriter within the meaning of Section 15 of the Securities Act, against any losses,
claims, damages or liabilities, joint or several, and expenses to which the Holder or any such director, officer, partner or underwriter
or controlling person may become subject under the Securities Act, the Exchange Act, or any other federal or state law, insofar
as such losses, claims, damages, liabilities or expenses (or actions or proceedings, whether commenced or threatened, in respect
thereof) arise out of or are based upon any untrue statement of any material fact contained in any registration statement prepared
and filed by the Company under which Registrable Securities were registered under the Securities Act, any preliminary prospectus,
final prospectus or summary prospectus contained therein, or any amendment or supplement thereto, or any omission to state therein
a material fact required to be stated or necessary to make the statements therein in light of the circumstances in which they were
made not misleading, or any violation or alleged violation of the Securities Act, the Exchange Act, any state securities law or
any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with this
Agreement; and the Company shall reimburse the Holder, and each such director, officer, partner, underwriter and controlling person
for any legal or any other expenses reasonably incurred by them in connection with investigating, defending or settling any such
loss, claim, damage, liability, action or proceeding; provided, that such indemnity agreement found in this Section 9(a)
shall in no event exceed the net proceeds from the PPO received by the Company; and provided further, that the Company shall
not be liable in any such case (i) to the extent that any such loss, claim, damage, liability (or action or proceeding in respect
thereof) or expense arises out of or is based upon an untrue statement in or omission from such registration statement, any such
preliminary prospectus, final prospectus, summary prospectus, amendment or supplement in reliance upon and in conformity with written
information furnished to the Company by the Holder specifically for use in the preparation thereof or (ii) if the person asserting
any such loss, claim, damage, liability (or action or proceeding in respect thereof) who purchased the Registrable Securities that
are the subject thereof did not receive a copy of an amended preliminary prospectus or the final prospectus (or the final prospectus
as amended or supplemented) at or prior to the written confirmation of the sale of such Registrable Securities to such person because
of the failure of such Holder or underwriter to so provide such amended preliminary or final prospectus and the untrue statement
or omission of a material fact made in such preliminary prospectus was corrected in the amended preliminary or final prospectus
(or the final prospectus as amended or supplemented). Such indemnity shall remain in full force and effect regardless of any investigation
made by or on behalf of the Holders, or any such director, officer, partner, underwriter or controlling person and shall survive
the transfer of such shares by the Holder.

 

    	 

    	 

    

 

(b)          As
a condition to including Registrable Securities in any registration statement filed pursuant to this Agreement, each Holder agrees
to be bound by the terms of this Section 9 and to indemnify and hold harmless, to the fullest extent permitted by law, the Company,
its directors and officers, and each other person, if any, who controls the Company within the meaning of Section 15 of the Securities
Act, against any losses, claims, damages or liabilities, joint or several, to which the Company or any such director or officer
or controlling person may become subject under the Securities Act, the Exchange Act, or any other federal or state law, to the
extent arising out of or based solely upon: (x) such Holder’s failure to comply with the prospectus delivery requirements
of the Securities Act or (y) any untrue or alleged untrue statement of a material fact contained in any registration statement,
any prospectus, or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising
out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the
statements therein not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained
in any information so furnished in writing by such Holder to the Company specifically for inclusion in the registration statement
or such prospectus or (ii) to the extent that (1) such untrue statements or omissions are based solely upon information regarding
such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information
relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly
approved in writing by such Holder expressly for use in the Registration Statement, such prospectus or such form of prospectus
or in any amendment or supplement thereto or (2) in the case of an occurrence of an event of the type specified in Section 4(f)
hereof, the use by such Holder of an outdated or defective prospectus after the Company has notified such Holder in writing that
the prospectus is outdated or defective and prior to the receipt by such Holder of the advice contemplated in Section 4(f). In
no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received
by such Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

(c)          Promptly
after receipt by an indemnified party of notice of the commencement of any action or proceeding involving a claim referred to in
this Section (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against
an indemnifying party, give written notice to the indemnifying party of the commencement of such action; provided, that
the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations
under this Section, except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. In
case any such action is brought against an indemnified party, unless in the reasonable judgment of counsel to such indemnified
party a conflict of interest between such indemnified and indemnifying parties may exist or the indemnified party may have defenses
not available to the indemnifying party in respect of such claim, the indemnifying party shall be entitled to participate in and
to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party and, after notice from the indemnifying
party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to
such indemnified party for any legal or other expenses subsequently incurred by the latter in connection with the defense thereof,
unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties
arises in respect of such claim after the assumption of the defenses thereof or the indemnifying party fails to defend such claim
in a diligent manner, other than reasonable costs of investigation. Neither an indemnified nor an indemnifying party shall be liable
for any settlement of any action or proceeding effected without its consent. No indemnifying party shall, without the consent of
the indemnified party, consent to entry of any judgment or enter into any settlement, which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such
claim or litigation. Notwithstanding anything to the contrary set forth herein, and without limiting any of the rights set forth
above, in any event any party shall have the right to retain, at its own expense, counsel with respect to the defense of a claim.

 

    	 

    	 

    

 

(d)          If
an indemnifying party does or is not permitted to assume the defense of an action pursuant to Sections 9(c) or in the case of the
expense reimbursement obligation set forth in Sections 9(a) and (b), the indemnification required by Sections 9(a) and 9(b) shall
be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills received
or expenses, losses, damages, or liabilities are incurred.

 

(e)          If
the indemnification provided for in Section 9(a) or 9(b) is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage or expense referred to herein, the indemnifying party, in lieu of indemnifying
such indemnified party hereunder, shall (i) contribute to the amount paid or payable by such indemnified party as a result of such
loss, liability, claim, damage or expense as is appropriate to reflect the proportionate relative fault of the indemnifying party
on the one hand and the indemnified party on the other (determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or omission relates to information supplied by the indemnifying party or the indemnified party
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement
or omission), or (ii) if the allocation provided by clause (i) above is not permitted by applicable law or provides a lesser sum
to the indemnified party than the amount hereinafter calculated, not only the proportionate relative fault of the indemnifying
party and the indemnified party, but also the relative benefits received by the indemnifying party on the one hand and the indemnified
party on the other, as well as any other relevant equitable considerations. No indemnified party guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any indemnifying party who was
not guilty of such fraudulent misrepresentation.

 

(f)          Other
Indemnification. Indemnification similar to that specified in this Section (with appropriate modifications) shall be given
by the Company and each Holder of Registrable Securities with respect to any required registration or other qualification of securities
under any federal or state law or regulation or governmental authority other than the Securities Act.

 

    	 

    	 

    

 

10.           Rule
144. With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the Commission
that may at any time permit the Holders to sell the Registrable Securities to the public without registration, the Company agrees:
(i) to make and keep public information available as those terms are understood in Rule 144, (ii) to file with the Commission in
a timely manner all reports and other documents required to be filed by an issuer of securities registered under the Securities
Act or the Exchange Act pursuant to Rule 144, (iii) as long as any Holder owns any Registrable Securities, to furnish in writing
upon such Holder’s request a written statement by the Company that it has complied with the reporting requirements of Rule
144 and of the Securities Act and the Exchange Act, and to furnish to such Holder a copy of the most recent annual or quarterly
report of the Company, and such other reports and documents so filed by the Company as may be reasonably requested in availing
such Holder of any rule or regulation of the Commission permitting the selling of any such Registrable Securities without registration
and (iv) undertake any additional actions commercially reasonably necessary to maintain the availability of the use of Rule 144.

 

11.           Independent
Nature of Each Purchaser’s Obligations and Rights. The obligations of each Purchaser under this Agreement are several
and not joint with the obligations of any other Purchaser, and each Purchaser shall not be responsible in any way for the performance
of the obligations of any other Purchaser under this Agreement. Nothing contained herein and no action taken by any Purchaser pursuant
hereto, shall be deemed to constitute such Purchasers as a partnership, an association, a joint venture, or any other kind of entity,
or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or
the transactions contemplated by this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights,
including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to
be joined as an additional party in any proceeding for such purpose.

 

12.           Other
Registration Rights. The Company shall not grant any additional registration rights other than those contemplated herein without
the consent of the Majority Holders prior to the effectiveness of the Registration Statement other than, in the case of the Company
(i) a registration relating solely to employee benefit plans or securities issued or issuable to employees, consultants (to the
extent the securities owned or to be owned by such consultants could be registered on Form S-8) or any of their Family Members
(including a registration on Form S-8) or (ii) a registration on Form S-4 in connection with a merger, acquisition, divestiture,
reorganization or similar event

 

13.           Miscellaneous.

 

(a)          Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the United States of America and the
State of New York, both substantive and remedial, without regard to New York conflicts of law principles. Any judicial proceeding
brought against either of the parties to this Agreement or any dispute arising out of this Agreement or any matter related hereto
shall be brought in the courts of the State of New York, New York County, or in the United States District Court for the Southern
District of New York and, by its execution and delivery of this Agreement, each party to this Agreement accepts the jurisdiction
of such courts. The foregoing consent to jurisdiction shall not be deemed to confer rights on any person other than the parties
to this Agreement.

 

(b)          Remedies.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder
or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement,
including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. The Company and each
Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it
of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance
in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

 

    	 

    	 

    

 

(c)          Successors
and Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon,
the successors, Permitted Assignees, executors and administrators of the parties hereto.

 

(d)          No
Inconsistent Agreements. The Company has not entered, as of the date hereof, and shall not enter, on or after the date of this
Agreement, into any agreement with respect to its securities that would have the effect of impairing the rights granted to the
Holders in this Agreement or otherwise conflicts with the provisions hereof.

 

(e)          Entire
Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the
subjects hereof.

 

(f)          Notices,
etc. All notices or other communications which are required or permitted under this Agreement shall be in writing and sufficient
if delivered by hand, by facsimile transmission, by registered or certified mail, postage pre-paid, by electronic mail, or by courier
or overnight carrier, to the persons at the addresses set forth below (or at such other address as may be provided hereunder),
and shall be deemed to have been delivered as of the date so delivered:

 

If to the Company to:

 

Corbus Pharmaceuticals Holdings, Inc.

One Kendall Square, Bldg 200,

Cambridge, MA 02139,

Attn: Yuval Cohen, CEO

E-mail: ycohen@corbuspharma.com

 

with copy to:

 

Lowenstein Sandler LLP

1251 Avenue of the Americas

New York, NY 10020

Attn: Steven M. Skolnick, Esq.

Facsimile: (973) 597 2477

 

If to the Purchasers:

 

To each Purchaser at the address set forth
on the signature page hereto or at such other address as any party shall have furnished to the other parties in writing.

 

    	 

    	 

    

 

(g)          Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any Holder, upon any breach or default
of the Company under this Agreement, shall impair any such right, power or remedy of such Holder nor shall it be construed to be
a waiver of any such breach or default, or an acquiescence therein, or of any similar breach or default thereunder occurring; nor
shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.
Any waiver, permit, consent or approval of any kind or character on the part of any Holder of any breach or default under this
Agreement, or any waiver on the part of any Holder of any provisions or conditions of this Agreement, must be in writing and shall
be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, or by law or
otherwise afforded to any holder, shall be cumulative and not alternative.

 

(h)          Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing
such counterparts, and all of which together shall constitute one instrument. In the event that any signature is delivered by facsimile
transmission or electronic transmission via .PDF file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or electronic signature
page were an original thereof.

 

(i)          Severability.
In the case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby.

 

(j)          Amendments.
The provisions of this Agreement may be amended at any time and from time to time, and particular provisions of this Agreement
may be waived, with and only with an agreement or consent in writing signed by the Company and the Majority Holders. The Purchasers
acknowledge that by the operation of this Section, the Majority Holders may have the right and power to diminish or eliminate all
rights of the Purchasers under this Agreement.

 

[SIGNATURE PAGES FOLLOW]

 

    	 

    	 

    

 

This Registration Rights
Agreement is hereby executed as of the date first above written.

 

	 	COMPANY:
	 	 
	 	CORBUS PHARMACEUTICALS HOLDINGS,

INC.
	 	 
	 	By: 	 
	 	Name:	Yuval Cohen 
	 	Title:	Chief Executive Officer

 

EACH PURCHASER’S
SIGNATURE TO THE SUBSCRIPTION AGREEMENT DATED OF

EVEN DATE HEREWITH
SHALL CONSTITUTE THE PURCHASER’S SIGNATURE TO

THIS REGISTRATION RIGHTS
AGREEMENT.

 

    	 

    	 

    

 

This Registration Rights
Agreement is hereby executed as of the date first above written.

 

JBT
Holders:

 

Entity: 

 

Name of Entity: _____________________

 

	By	 	 
	 	Name and Title: ________________	 
	 	 	 
	 	Address: ________________	 
	 	 	 
	 	               ________________	 
	 	 	 
	 	Email:  ____________________	 

 

Individual: 

 

	By	 	 
	 	Name: ________________	 
	 	Address: ________________	 
	 	 	 
	 	               ________________	 
	 	 	 
	 	Email:  ___________________	 

 

    	 

    	 

    

 

ANNEX A

 

JBT Holders

 

JBT Preferred Holders 

 

Peter Aranow

Philip Morgan

Amar Kapur

Lisa Kirby-Gibbs

Rohit D, Vakil

Bhalchandra G Parulkar

Sandeep Shah

John B. Goodrich

Michael Gregoire

Lee Chartrock

Lauer- Williams Family Trust

Donald E. Bates

Diamond Management Holdings (legal name: Diamond MGT)

Allen Michel (aka "Alan Michel")

Floyd Roos Properties LLC (Warren Roos )

George Xixis

Brenden Mckernan Courtagen Angel Fund

Equity Trust Co Cust FBO Lawrence Mintzer IRA

McKernan Family Partnership - Brendan McKernan

Carl Berke

Mark Butler

Stuart Wolpoff and Lee Rosner JTWROS

Venture Law Inc, Kenneth Merritt Defined Pension Plan

John M. Dacey

Howard Bilow

Richard Fedorowich

Karen Donovan

Jeff Arnold

Richard Anders

Andrew & Barbara J. Douglas

Michael Mark

Berenson Ventures, Richard Berenson

Mark R Cote

Terry Plasse

Bilcare-Sharpe

Anup Patel

Ethan S. Burstein

 

    	 

    	 

    

 

JBT Warrant Holders 

 

Peter Aranow

Philip Morgan

Amar Kapur

Lisa Kirby-Gibbs

Rohit D, Vakil

Bhalchandra G Parulkar

Sandeep Shah

Amon Mandelbaum

NLBDIT 2010 Enterprises LLC

Sunrise Foundation Trust

 

    	 

    	 

    

 

Exhibit A 

 

Selling Stockholder Questionnaire

 

[See Attached.]

 

    	 

    	 

    

 

CORBUS PHARMACEUTICALS HOLDINGS, INC.

STOCKHOLDERS’ QUESTIONNAIRE

 

The following information
is requested from you in connection with the preparation and filing by Corbus Pharmaceuticals Holdings, Inc. (the “Company”)
of a Registration Statement on Form S-1 or other appropriate form (the “Registration Statement”) with the Securities
and Exchange Commission (the “SEC”) covering the sale of shares of the Company’s common stock, including shares
of common stock underlying certain Warrants (the “Registrable Securities”) by certain stockholders of the Company.

 

We would appreciate
your answering all of the questions included in this questionnaire, even though your answers may be in the negative, so that the
Company will have a record of your responses for use in connection with the preparation of the Registration Statement. It is
requested that you give careful attention to each question and that you complete this questionnaire personally.

 

In order to assist
you in completing this questionnaire, certain terms used herein are defined in the appendix which is attached to this questionnaire.
Each of such defined terms has been bolded and italicized for identification. The term “person,” as used
in this questionnaire, means any natural person, company, government or political subdivision, agency or instrumentality of a government.

 

After you have
completed the following questionnaire, please send the completed questionnaire by e-mail at kdougherty@lowenstein.com or
overnight courier as soon as possible to the attention of Kate Dougherty, Esq. at Lowenstein Sandler LLP, 1251 Avenue of the Americas,
17th Floor, New York, NY 10020.

 

*********************

 

    	 

    	 

    

 

General
Information

 

1.          Please
provide your full name and address or the full name and address of the entity on whose behalf you are completing this questionnaire.
The address may be a business, mailing or residence address.

 

	Name:	 

 

	Address:	 

 

If you are answering this questionnaire
on behalf of a corporate entity, please state your name and position with the selling shareholder.

 

	Name:	 

 

	Position:	 

 

		2.	Name the Control Person of your organization: _________________________________

 

		3.	(a) Are you a broker-dealer registered pursuant to Section 15 of the Exchange Act?

 

	 	 ̈  Yes 	 ̈  No	 

 

(b) If your response to Item 3(a) above is no, are
you an "affiliate"1 of a broker-dealer registered pursuant to Section 15 of the Exchange Act?

 

	 	 ̈  Yes 	 ̈  No	 

 

(c) Please provide the full legal name of the person
through which you hold the Registrable Securities—(i.e. name of your broker, if applicable, through which your Registrable
Securities are held):

 

	 	Name of broker:	 
	 	 	 
	 	Contact person:	 
	 	 	 
	 	Telephone No.:	 

 

 

1 For the purposes of this Item 3(b), an "affiliate"
of a registered broker dealer shall include any company that directly, or indirectly through one or more intermediaries, controls,
or is controlled by, or is under common control with, such broker dealer, and does not include any individuals employed by such
broker dealer or its affiliates.

 

    	 

    	 

    

 

Securities
Holdings

 

Existing Holders:

 

Please fill in all
blanks in the following questions related to your beneficial ownership of the Company’s common stock.

Generally, a beneficial
owner of a security is a person who, directly or indirectly, through any contract, arrangement, understanding, relationship
or otherwise has or shares either:

(i) voting power, which includes
the power to vote, or to direct the voting of such security; and/or

(ii) investment power, which
includes the power to dispose, or to direct the disposition of, such security, even though he or she may not be the holder of record
of the securities.

 

Thus, securities held
in “street name” over which you exercise voting or investment power would be considered beneficially owned
by you. Other examples of indirect ownership include ownership by a partnership in which you are a partner or by an estate or trust
of which you or any member of your immediate family is a beneficiary. Ownership of securities held in the names of
your spouse, minor children or other relatives who live in the same household may be attributed to you.

If you have any reason
to believe that any interest in securities of the Company which you may have, however remote, is a beneficial interest, please
describe such interest. For purposes of responding to this questionnaire, it is preferable to err on the side of inclusion rather
than exclusion.

Where the SEC’s
interpretation of beneficial ownership would require disclosure of your interest or possible interest in certain
securities of the Company, and you believe that you do not actually possess the attributes of beneficial ownership,
an appropriate response is to disclose the interest and at the same time disclaim beneficial ownership of the securities.

 

Please indicate the amount of common
stock of the Company or any of its subsidiaries which you beneficially owned as of the date hereof.

  

	Number of

Shares	Registered in

the Name of	Beneficially

Owned by	Shares to be 

Sold	Remarks
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

For each holding:

 

		·	State the nature of the holding (i.e., held in your own name, jointly, as a trustee or beneficiary
of a trust, as a custodian, as an executor, in discretionary accounts, by your spouse or minor children, by a partnership of which
you are a partner, etc.), and

 

    	 

    	 

    

 

		·	State whether you are the beneficial owner by reason of (i) sole voting power, (ii)
shared voting power, (iii) sole investment power, (iv) shared investment power, (v) the right to acquire stock within 60 days of
the end of the calendar year, (vi) the right to acquire stock with the purpose of changing or influencing control; and/or (vii)
a security-based swap that you hold that gives you voting or investment power over the underlying Company stock (even though you
may not directly hold the underlying Company stock).

 

		·	Indicate in the Remarks column below whether you have sole or shared voting or investment power
with respect to any such securities, and in what capacity (i.e., individual, general partner, trustee) you have such power
or powers.

 

		·	If you wish to disclaim beneficial ownership of any shares listed, so indicate by
writing the word “Disclaim” in the Remarks column below; you understand that such shares will be shown separately from
your beneficial holdings and an appropriate disclaimer set forth.

 

		·	If any of the shares listed are subject to any claim, encumbrance, pledge or lien, so indicate
in the Remarks column.

 

    	 

    	 

    

 

Existing Holders and New Investors:

 

	1.	Your Interest in the Registrable Securities 

 

	 	(a)	State the number of such Registrable Securities beneficially owned by you. 

 

	 	Common stock:	 
	 	 	 
	 	Warrants:	 

 

(b)          Other
than as set forth in your response to Item 1(a) above, do you beneficially own any other securities of the Company?

 

	 	 ̈  Yes	 ̈  No

 

(c)          If
your answer to Item 1(b) above is yes, state the type, the aggregate amount and CUSIP No. (if applicable) of such other securities
of the Company beneficially owned by you:

 

	 	Type:	 

 

	 	Aggregate amount:	 

 

	 	CUSIP No.:	 

 

(d)          Did
you acquire the securities listed in Item 1(a) above in the ordinary course of business?

	 	 ̈  Yes 	 ̈  No

 

(e)          At
the time of your purchase of the securities listed in Item 1(a) above, did you have any agreements or understandings, directly
or indirectly, with any person to distribute the securities?

	 	 ̈  Yes 	 ̈  No 

 

(f)          If
your response to Item 1(e) above is yes, please describe such agreements or understandings:

 

	 
	 
	 
	 
	 

 

    	 

    	 

    

 

2.          Nature
of Your Beneficial Ownership

 

(a)          Does
someone other than you have control over the securities listed in Item 1(a) above?

	 	 ̈  Yes	 ̈  No

 

(b)          If
your response to Item 2(a) above is yes, name your controlling shareholder(s) or other person who has the ability to exercise control
over you (the "Controlling Entity"). If the Controlling Entity is not a natural person and is not a publicly held entity,
name each shareholder of such Controlling Entity. If any of these named shareholders are not natural persons or publicly held entities,
please provide the same information. This process should be repeated until you reach natural persons or a publicly held entity.

 

	 	(A)(i)	Full legal name of Controlling Entity(ies) or natural person(s) with who have sole or shared voting or dispositive power over the Registrable Securities:
	 	 	Business address (including street address) (or residence if no business address), telephone number and facsimile number of such person(s):

	 	Address:	 

	 	 

	 	Telephone:	 

	 	Fax:	 

	 	Name of shareholder:	 

	 	 

	 	 

	 	(B)(i)	Full legal name of Controlling Entity(ies):
	 	 	 
	 	 	 
	 	 	Business address (including street address) (or residence if no business address), telephone number and facsimile number of such person(s):

	 	Address:	 

	 	 

	 	Telephone:	 

	 	Fax:	 

	 	Name of shareholders:	 

	 	 

 

If you need more space for this response, please attach additional
sheets of paper. Please be sure to indicate your name and the number of the item being responded to on each such additional sheet
of paper, and to sign each such additional sheet of paper before attaching it to this Questionnaire.

 

    	 

    	 

    

 

Please note that you may be asked to answer additional questions
depending on your responses to the following questions.

 

3.          5%
Stockholders

Do you or any of your associates
(including corporations, partnerships, trusts, associations and other such groups) beneficially own more than 5%
of any class of the Company’s stock?

 

	 	 ̈  Yes	 ̈  No

 

If the answer is yes, please describe
such persons and their holdings below:

 

	Name of

Beneficial

Owner	 	Class of Shares

Beneficially

Owned	 	Holder of

Voting or

Investment Power
	 	 	 	 	 
	 	 	 	 	 

 

4.          No
Adverse Interest 

Do or will you or any of your associates have
any interests that are adverse to the Company interests in any pending or contemplated legal proceeding or government investigation
to which the Company is or will be a party (or to which its property may be subject)?

 

	 	 ̈  Yes	 ̈  No

 

If yes, please describe such interests below:

 

5.          Voting Arrangement

Do you have knowledge of any voting trusts or similar agreements
or arrangements pursuant to which more than 5% of the Company’s outstanding common stock, on an as converted
basis, is subject are described below:

 

	 	 ̈  Yes	 ̈  No

 

If yes, please describe such agreements or arrangements
below:

	Names and Addresses of Voting Trustees	 	Voting Rights and Other Powers

Under Trust, Agreement or Arrangement
	 	 	 

 

    	 

    	 

    

 

6.          Change
in Control

Are you aware of any arrangements, including any
pledge by any person of securities of the Company, the operations of which may at a subsequent date result in a change in control
of the Company?

 

	 	 ̈  Yes	 ̈  No

 

If yes, please describe such arrangements below:

 

7.          Transactions
with the Company

Have your or any of your associates had
any material interests in any actual or proposed transaction during the last three fiscal years to which the Company
was or is to be a party (and that are identified under “Securities Holdings” above)?

 

	 	 ̈  Yes	 ̈  No

 

If yes, please describe such interests below:2

 

8.          Affiliation
with Accountants or Attorneys

Do you have any interest, affiliation or connection with any
law firm or accounting firm that has been retained by the Company during the last three fiscal years or is proposed to be retained
by the Company?

 

	 	 ̈  Yes	 ̈  No

 

If yes, please describe such interest, affiliation or
connection below:

 

 

2 No such transaction need be described if:

(a) the amount involved (including all periodic installments
in the case of any lease or other agreement provided for periodic payments or installments and including the value of all transactions
In a series of similar transactions) does not exceed $60,000;

(b) the rates or charges involved in the transaction are fixed
by law or governmental authority or determined by competitive bids;

(c) the services involved are as a bank depositary of funds,
transfer agent, registrar, trustee under a trust indenture or other similar service;

(d) your interest arises solely from my ownership of securities
of the Company and you received no extra or special benefit not shared on a pro rata basis by all other holders of securities in
the same class;

(e) your interest in the corporation that is a party to the
transaction is solely as a director; or

(f) your interest arose solely as an officer and/or director
of the Company (e.g., your compensation arrangement with the Company).

 

    	 

    	 

    

 

9.          Contracts
with the Company

Are you or any of your associates
a party to any contracts with the Company or in which the Company has a beneficial interest, or to which the Company has succeeded
by assumption or assignment, which are to be performed in whole or in part at or after the date of the proposed filing of the Registration
Statement, or which were made not more than two years prior thereto?

 

	 	 ̈  Yes	 ̈  No

 

If yes, please describe such contract(s) below:

 

    	 

    	 

    

 

FINRA-Related
Questions

 

1.          Are
you (i) a “member” of the Financial Industries Regulatory Authority, Inc. (“FINRA”), (ii) an “affiliate”
of a member of FINRA, (iii) a “person associated with a member” or “associated person of a member” of FINRA
or (iv) associated with an “underwriter or related person” with respect to the proposed public offering of the Company’s
securities?

 

	 	Yes   ̈ No    ̈

 

For the sole purpose of this Question:
(i) FINRA generally defines a “member” to include any broker or dealer admitted to membership in FINRA or any officer
or partner of such a member or the executive representative of such member or the substitute for such representative; (ii) the
term “affiliate” means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled
by, or is in common control with the person specified. Persons who have acted or are acting on behalf or for the benefit of a person
include, but are not necessarily limited to, directors, officers, employees, agents, consultants and sales representatives; (iii)
FINRA generally defines a “person associated with a member” or “associated person of a member” to include
every sole proprietor, partner, officer, director or branch manager of any member, or any natural person occupying a similar status
or performing similar functions, or any natural person engaged in the investment banking or securities business who is directly
or indirectly controlling or controlled by such member (for example, any employee), whether or not any such person is registered
or exempt from registration with FINRA; and (iv) the term “underwriter or related person” includes, with respect to
a proposed offering, underwriters, underwriters’ counsel, financial consultants and advisers, finders, members of the selling
or distribution group, and any and all other persons associated with or related to any such persons.

 

If yes, kindly describe such relationship
(whether direct or indirect) and please respond to Questions (2) and (3) below; if no, please proceed to Question (4).

 

2.          Please
set forth information as to all purchases and acquisitions (including contracts for purchase or acquisition) of securities of the
Company by you, regardless of the time acquired or the source from which derived:

 

	Seller or	Amount and	Price or Other	 
	Prospective Seller	Nature of Securities	Consideration	Date
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

3.          In
connection with your direct or indirect affiliation or association with a “member” of FINRA as set forth above in Question
(1), please furnish the identity of such FINRA member and any information, if known, as to whether such FINRA member intends to
participate in any capacity in this proposed initial public offering, including the details of such participation:

 

    	 

    	 

    

 

4.          Please
describe any underwriting compensation and arrangement or any dealings known to you between any “underwriter or related person”,
“member” of FINRA, “affiliate” of a member of FINRA, “person associated with a member”, or
“associated person of a member” of FINRA on the one hand and the Company or controlling shareholder thereof on the
other hand, other than information relating to the proposed initial public offering of the Company:

 

5.          Please
set out below any information, if known, as to whether any “member” of FINRA, any “underwriter or related person”,
“affiliate” or a member of FINRA, “person associated with a member” or “associated person of a member”
of FINRA may receive any portion of the net offering:

 

For subscribers answering “Yes”
to Item 1 above:

 

The undersigned FINRA member form acknowledges receipt of the
notice required by Article 3, Sections 28(a) and (b) of the Rules of Fair Practice.

 

	 	 
	Name of FINRA Member Firm	 

 

	By:	 	 	Date:	 	 
	 	Authorized Officer	 	 	 	 

 

    	 

    	 

    

 

The undersigned
(including its donees or pledgees) intends to distribute the Registrable Securities listed above pursuant to the Registration Statement
only as follows (if at all): Such Registrable Securities may be sold from time to time directly by the undersigned or, alternatively,
through underwriters, broker-dealers or agents. If the Registrable Securities are sold through underwriters, broker-dealers or
agents, the selling holder will be responsible for underwriting discounts or commissions or agents' commissions. Such Registrable
Securities may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying
prices determined at the time of sale or at negotiated prices. Such sales may be effected in transactions (which may involve block
transactions) (i) on any national securities exchange or quotation service on which the Registrable Securities may be listed or
quoted at the time of sale, (ii) in the over-the-counter market, or (iii) in transactions otherwise than on such exchanges or services
or in the over-the-counter market.

 

I understand that material
misstatements or the omission of material facts in the Registration Statement may give rise to civil and criminal liabilities to
the Company, to each officer and director of the Company signing the Registration Statement and other persons signing the Registration
Statement. I will notify you and the Company of any misstatement of a material fact in the Registration Statement or any amendment
thereto, and of the omission of any material fact necessary to make the statements contained therein not misleading, as soon as
practicable after a copy of the Registration Statement or any such amendment has been provided to me.

 

I confirm that the foregoing statements
are correct, to the best of my knowledge and belief.

 

Dated:  _____________________.

 

	 	Very truly yours,	 
	 	 	 
	 	 	 
	 	(Signature)	 
	 	 	 
	 	 	 
	 	(Typed or Printed Name)	 

 

    	 

    	 

    

 

Definitions

 

The term “arrangement”
means any plan, contract, authorization or understanding whether or not set forth in a formal document.

 

The term “associate”
as used throughout this questionnaire, means (a) any corporation or organization (other than the Company) of which I am an officer,
director or partner or of which I am, directly or indirectly, the beneficial owner of 5% or more of any class of equity securities,
(b) any trust or other estate in which I have a substantial beneficial interest or as to which I serve as trustee or in a similar
capacity, (c) my spouse, (d) any relative of my spouse or any relative of mine who has the same home as me or who is a director
or officer or key executive of the Company, (e) any partner, syndicate member or person with whom I have agreed to act in concert
with respect to the acquisition, holding, voting or disposition of shares of the Company’s securities.

 

The term “beneficially owned”
when used in connection with the ownership of securities, means (a) any interest in a security which entitles me to any of
the rights or benefits of ownership even though I may not be the owner of record or (b) securities owned by me directly or indirectly,
including those held by me for my own benefit (regardless of how registered) and securities held by others for my benefit (regardless
of how registered), such as by custodians, brokers, nominees, pledgees, etc., and including securities held by an estate or trust
in which I have an interest as legatee or beneficiary, securities owned by a partnership of which I am a partner, securities held
by a personal holding company of which I am a stockholder, etc., and securities held in the name of my spouse, minor children and
any relative (sharing the same home). A “beneficial owner” of a security includes any person who, directly or indirectly,
through any contract, arrangement, understanding, relationship or otherwise has or shares:

 

(a)          voting
power which includes the power to vote, or to direct the voting of, such security; and/or

 

(b)          investment
power which includes the power to dispose, or to direct the disposition, of such security.

 

The term “control”
(including the terms “controlling,” “controlled by” and “under common control with”) means
the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person,
whether through the ownership of voting securities, by contract or otherwise.

 

The term “immediate family”
means any relationship by blood, marriage or adoption, not more remote than first cousin.

 

The term “material,”
when used in this questionnaire to qualify a requirement for the furnishing of information as to any subject, limits the information
required to those matters as to which an average prudent investor ought reasonably to be informed before purchasing the Common
Stock of the Company.Exhibit 10.1

 

PLACEMENT AGENCY AGREEMENT

 

March 27, 2014

 

Aegis Capital Corp.

810 Seventh Ave, 11th Floor

New York, NY 10019

 

		Re:	JB Therapeutics, Inc. and Corbus Pharmaceuticals Holdings,
Inc.

 

Ladies and Gentlemen:

 

This Placement Agency
Agreement ("Agreement") sets forth the terms upon which Aegis Capital Corp., a New York corporation, and a registered
broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") (the “Placement Agent”),
shall be engaged by JB Therapeutics, Inc., a Delaware corporation (“JBT”) and Corbus Pharmaceuticals Holdings,
Inc., a Delaware corporation (“Issuer”), to act as exclusive Placement Agent in connection with the private
placement (the “Offering”) of units (“Units”) of securities of Issuer, with each Unit consisting
of (i) 250,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), of Issuer (the “Shares”)
and (ii) 250,000 warrants (the “Warrants”), with each Warrant entitling the holder to purchase one share of
Common Stock for a five-year period at an exercise price of $1.00 per share. The Offering will consist of a minimum of 18 Units
($4,500,000) (the “Minimum Amount”) and a maximum of 36 Units ($9,000,000) (the “Maximum Amount”).
In the event the Offering is oversubscribed, JBT and the Placement Agent may, in their mutual discretion, have Issuer sell up to
16 additional Units for an additional aggregate purchase price of $4,000,000 (the “Over-allotment”). Concurrently
with the initial closing of the Offering, a wholly-owned subsidiary of Issuer will merge with and into JBT and, with the proceeds
of the Offering, will continue the existing operations of JBT as a wholly owned subsidiary of Issuer by the name of Corbus Pharmaceuticals,
Inc. (the “Merger”).

 

As part of or in conjunction
with the Merger, Issuer will issue shares of its Common Stock and warrants to (i) JBT’s then-existing securityholders as
the consideration in the Merger pursuant to the terms of the Merger Agreement dated the date hereof among JBT, Issuer and a subsidiary
of Issuer (the “Merger Agreement”) and (ii) the investors in the Offering as further described in the Memorandum
(as hereinafter defined). As used in this Agreement, unless the context otherwise requires, the term “Company”
refers to Issuer and JBT on a combined basis after giving effect to the Offering and the Merger.

 

The purchase price
for the Units will be $250,000 per Unit (the “Offering Price”), with a minimum investment of one Unit; provided,
however, that subscriptions for lesser amounts may be accepted in JBT’s and Placement Agent’s joint discretion.
The Placement Agent shall accept subscriptions
only from persons or entities who qualify as “accredited investors,” as such term is defined in Rule 501 of Regulation
D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”). The Units will be offered
until the earlier of (i) the termination of the Offering as provided herein, (ii) the time that all Units offered in the Offering
are sold or (iii) May __, 2014 [60 days from PPM] (“Initial Offering Period”), which date may be extended
by the Placement Agent and JBT in their joint discretion until June __, 2014 [additional 30 days] (this additional period
and the Initial Offering Period shall be referred to as the “Offering Period”). The date on which the Offering
expires or is terminated shall be referred to as the “Termination Date.” 

 

    	 

    	 

    

  

With respect to the
Offering, JBT and Issuer shall provide the Placement Agent, on terms set forth herein, the right to offer and sell all of the Units
being offered. Purchases of Units may be made by the Placement Agent and its officers, directors, employees and affiliates. All
such purchases, together with purchases by officers, directors, employees and affiliates of JBT or Issuer, may be used to satisfy
the Minimum Amount if the Minimum Amount has not been subscribed for on or before the end of the Offering Period. It is understood
that no sale shall be regarded as effective unless and until accepted by the Issuer and JBT. The Issuer and JBT may, in their joint
discretion, accept or reject, in whole or in part, any prospective investment in the Units. JBT and the Placement Agent shall mutually
agree with respect to allotting any prospective subscriber less than the number of Units that such subscriber desires to purchase.

 

The Offering will be
made by Issuer solely pursuant to the Memorandum, which at all times will be in form and substance reasonably acceptable to Issuer,
JBT, the Placement Agent and their respective counsel and contain such legends and other information as Issuer, JBT, the Placement
Agent and their respective counsel, may, from time to time, deem necessary and desirable to be set forth therein. “Memorandum”
as used in this Agreement means Issuer’s Confidential Private Placement Memorandum dated on or about March __, 2014, inclusive
of all annexes, and all amendments, supplements and appendices thereto.

 

1.           Appointment
of Placement Agent. On the basis of the representations and warranties provided herein, and subject to the terms and conditions
set forth herein, the Placement Agent is appointed as exclusive Placement Agent for JBT and Issuer during the Offering Period
to assist JBT and Issuer in finding qualified subscribers for the Offering. The Placement Agent may sell Units through other broker-dealers
who are FINRA members and may reallow all or a portion of the Agent Compensation (as defined in Section 3(b) below) it receives
to such other broker-dealers. Placement Agent shall provide prompt notification to the Company to the extent such other broker-dealers
are engaged. On the basis of such representations and warranties and subject to such terms and conditions, the Placement Agent
hereby accepts such appointment and agrees to perform its services hereunder diligently and in good faith and in a professional
and businesslike manner and to use its reasonable efforts to assist JBT and Issuer in (A) finding subscribers of Units who qualify
as “accredited investors,” as such term is defined in Rule 501 of Regulation D, and (B) completing
the Offering. The Placement Agent has no obligation to purchase any of the Units. Unless sooner terminated in accordance
with this Agreement, the engagement of the Placement Agent hereunder shall continue until the later of the Termination Date or
the Final Closing (as defined below).

 

2.           Representations,
Warranties and Covenants of JBT. The representations, warranties and covenants of JBT (as used in this Section 2, “JBT”
refers to JB Therapeutics, Inc. and its subsidiaries, if any) to the Placement Agent contained in this Section 2 are true and correct
as of the date of this Agreement.

 

    	2

    	 

    

  

(a)          The
Memorandum has been prepared by JBT, in conformity with all applicable laws, and is in compliance in all material respects with
Regulation D and Section 4(a)(2) of the Act and the requirements of all other rules and regulations (the “Regulations”)
of the SEC relating to offerings of the type contemplated by the Offering, and the applicable securities laws and the rules and
regulations of those jurisdictions wherein the Placement Agent notifies JBT that the Units are to be offered and sold excluding
any foreign jurisdictions. The Units will be offered and sold pursuant to the registration exemption provided by Regulation D and
Section 4(a)(2) of the Act as a transaction not involving a public offering and the requirements of any other applicable state
securities laws and the respective rules and regulations thereunder in those United States jurisdictions in which the Placement
Agent notifies JBT that the Units are being offered for sale. None of JBT, its affiliates, or any person acting on its or their
behalf (other than the Placement Agent, its affiliates or any person acting on its behalf, in respect of which no representation
is made) has taken nor will it take any action that conflicts with the conditions and requirements of, or that would make unavailable
with respect to the Offering, the exemption(s) from registration available pursuant to Rule 506(b) of Regulation D or Section 4(a)(2)
of the Act, or knows of any reason why any such exemption would be otherwise unavailable to it. None of JBT, its predecessors or
affiliates has been subject to any order, judgment or decree of any court of competent jurisdiction temporarily, preliminarily
or permanently enjoining such person for failing to comply with Section 503 of Regulation D. Except for the sale of 103,642 shares
of Series A preferred stock, JBT has not, for a period of six months prior to the commencement of the offering of Units, sold,
offered for sale or solicited any offer to buy any of its securities in a manner that would be integrated with the offer and sale
of the Units pursuant to this Agreement and would cause the exemption from registration set forth in Rule 506(b) of Regulation
D to become unavailable with respect to the offer and sale of the Units pursuant to this Agreement in the United States.

 

(b)          The
Memorandum does not include any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading: provided,
however, the foregoing does not apply to any statements or omissions made solely in reliance on and in conformity with written
information furnished to JBT by Issuer or the Placement Agent specifically for use in the preparation thereof. To the knowledge
of JBT, none of the statements, documents, certificates or other items made, prepared or supplied by JBT with respect to the transactions
contemplated hereby contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements
contained therein not misleading in light of the circumstances in which they were made. There is no fact which JBT has not disclosed
in the Memorandum and of which JBT is aware that materially adversely affects or that could reasonably be expected to have a material
adverse effect on the (i) assets, liabilities, results of operations, condition (financial or otherwise), business or business
prospects of JBT or (ii) the ability of JBT to perform its obligations under this Agreement. Notwithstanding anything to the contrary
herein, JBT makes no representation or warranty with respect to any estimates, projections and other forecasts and plans (including
the reasonableness of the assumptions underlying such estimates, projections and other forecasts and plans) that may have been
delivered to the Placement Agent or its representatives or that are contained in the Memorandum, except that such estimates, projections
and other forecasts and plans have been prepared in good faith on the basis of assumptions stated therein, which assumptions were
believed to be reasonable at the time of such preparation.

 

    	3

    	 

    

  

(c)          JBT
is duly organized and validly existing in good standing under the laws of the jurisdiction in which it was formed, and has the
requisite power and authority to own its properties and to carry on its business as now being conducted. JBT is not a participant
in any joint venture, partnership or similar arrangement and does not directly or indirectly own any subsidiaries or otherwise
own or hold capital stock or an equity or similar interest in any entity. JBT is duly qualified as a foreign entity to do business
and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it
makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have
a JBT Material Adverse Effect. As used in this Agreement, “JBT Material Adverse Effect” means any material
adverse effect on the business, properties, assets, operations, results of operations or condition (financial or otherwise) of
JBT, taken as a whole, or on the transactions contemplated hereby and the other JBT Transaction Documents (as defined below) or
by the agreements and instruments to be entered into in connection herewith or therewith, or on the authority or ability of JBT
to perform its obligations under the JBT Transaction Documents (as defined below).

 

(d)          JBT
has all requisite corporate power and authority to conduct its business as presently conducted and as proposed to be conducted
(as described in the Memorandum), to enter into and perform its obligations under this Agreement, the Subscription Agreement substantially
in the form of Annex A to the Memorandum (the “Subscription Agreement”), the Registration Rights Agreement substantially
in the form of Annex B to the Memorandum (the “Registration Rights Agreement”), and the other agreements contemplated
hereby (this Agreement, the Subscription Agreement, the Registration Rights Agreement and the other agreements contemplated hereby
that JBT is executing and delivering hereunder are collectively referred to herein as the “JBT Transaction Documents”).
Prior to the initial closing of this Offering (the “First Closing”), each of the JBT Transaction Documents (other
than this Agreement, which has already been authorized) will have been duly authorized. This Agreement has been duly authorized,
executed and delivered and constitutes, and each of the other JBT Transaction Documents, upon due execution and delivery, will
constitute, valid and binding obligations of JBT, enforceable against JBT in accordance with their respective terms (i) except
as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws now or
hereafter in effect related to laws affecting creditors’ rights generally, including the effect of statutory and other laws
regarding fraudulent conveyances and preferential transfers, and except that no representation is made herein regarding the enforceability
of JBT’s obligations to provide indemnification and contribution remedies under the securities laws and (ii) subject to the
limitations imposed by general equitable principles (regardless of whether such enforceability is considered in a proceeding at
law or in equity).

 

    	4

    	 

    

  

(e)          None
of the execution and delivery of or performance by JBT under this Agreement or any of the other JBT Transaction Documents or the
consummation of the transactions herein or therein contemplated conflicts with or violates, or will result in the creation or imposition
of, any lien, charge or other encumbrance upon any of the assets of JBT under any agreement or other instrument to which JBT is
a party or by which JBT or its assets may be bound, or any term of the certificate of incorporation or by-laws of JBT, or any license,
permit, judgment, decree, order, statute, rule or regulation applicable to JBT or any of its assets, except in the case of a conflict,
violation, lien, charge or other encumbrance (except with respect to JBT’s Certificate of Incorporation or By-laws) which
would not reasonably be expected to have a JBT Material Adverse Effect.

 

(f)           JBT’s
unaudited financial statements, together with the related notes, if any, included in the Memorandum, present fairly, in all material
respects, the financial position of JBT as of the dates specified and the results of operations for the periods covered thereby.
Such unaudited financial statements and related notes were prepared to conform with United States generally accepted accounting
principles applied on a consistent basis throughout the periods indicated. Except as set forth in such financial statements or
otherwise disclosed in the Memorandum, JBT has no known material liabilities of any kind, whether accrued, absolute or contingent,
or otherwise, and subsequent to the date of the Memorandum and prior to the date of the First Closing it shall not enter into any
material transactions or commitments without promptly thereafter notifying the Placement Agent in writing of any such material
transaction or commitment. The other financial and statistical information with respect to JBT and any pro forma information and
related notes included in the Memorandum present fairly in all material respects the information shown therein on a basis consistent
with the financial statements of JBT included in the Memorandum. JBT does not know of any facts, circumstances or conditions
which could materially adversely affect its operations, earnings or prospects that have not been fully disclosed in the Memorandum.

 

(g)          Except
as disclosed in the Memorandum, since the date of JBT’ most recent financial statements contained in the Memorandum, there
has been no JBT Material Adverse Effect. Except as disclosed in the Memorandum, since the date of JBT’s most recent financial
statements contained in the memorandum, JBT has not (i) declared or paid any dividends, (ii) sold any assets, individually or in
the aggregate, in excess of $75,000 outside of the ordinary course of business or (iii) had capital expenditures, individually
or in the aggregate, in excess of $75,000. JBT has not taken any steps to seek protection pursuant to any bankruptcy law nor does
JBT have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any actual
knowledge of any fact which would reasonably lead a creditor to do so.

 

    	5

    	 

    

  

(h)          Except
as disclosed in the Memorandum, JBT (i) has no outstanding Indebtedness (as defined below) in excess of $75,000, (ii) is not a
party to any contract, agreement or instrument, the violation of which, or default under which, by the other party(ies) to such
contract, agreement or instrument would result in a Material Adverse Effect, or (iii) is not in violation of any term of or in
default under any contract, agreement or instrument relating to any Indebtedness, except where such violations and defaults would
not result, individually or in the aggregate, in a Material Adverse Effect. For purposes of this Agreement: (x) “Indebtedness”
of any Person means without duplication, (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed
as the deferred purchase price of property or services including (without limitation) “Capital Leases” (as defined
under GAAP) (other than trade payables entered into in the ordinary course of business), (C) all reimbursement or payment obligations
with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures
or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses,
(E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing,
in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even though the rights and
remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property),
(F) all monetary obligations under any leasing or similar arrangement which, in connection with GAAP, consistently applied for
the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above
secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any
mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts and
contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or become liable
for the payment of such indebtedness, and (H) except for obligations owed to service providers of JBT in connection with this Offering,
all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through
(G) above of at least $75,000; (y) “Contingent Obligation” means, as to any Person, any direct or indirect liability,
contingent or otherwise, of that Person with respect to any indebtedness, lease, dividend or other obligation of another Person
if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance
to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be
complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto;
and (z) “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.

 

(i)           The
conduct of business by JBT as presently and proposed to be conducted is not subject to continuing oversight, supervision, regulation
or examination by any governmental official or body of the United States, or any other jurisdiction wherein JBT conducts or proposes
to conduct such business, except as described in the Memorandum. JBT has obtained all material licenses, permits and other governmental
authorizations necessary to conduct its business as presently conducted. JBT has not received any notice of any violation of, or
noncompliance with, any federal, state, local or foreign laws, ordinances, regulations and orders (including, without limitation,
those relating to environmental protection, occupational safety and health, securities laws, equal employment opportunity, consumer
protection, credit reporting, “truth-in-lending”, and warranties and trade practices) applicable to its business, the
violation of, or noncompliance with, would have an JBT Material Adverse Effect, and JBT knows of no facts or set of circumstances
which could give rise to such a notice.

 

(j)          No
default by JBT or, to the knowledge of JBT, any other party, exists in the due performance under any material agreement to which
JBT is a party or to which any of its assets is subject (collectively, the “JBT Agreements”). The JBT Agreements
disclosed in the Memorandum are the only material agreements to which JBT is bound or by which its assets are subject, are accurately
described in the Memorandum and are in full force and effect in accordance with their respective terms, subject to any applicable
bankruptcy, insolvency or other laws affecting the rights of creditors generally and to general equitable principles and the availability
of specific performance.

 

    	6

    	 

    

  

(k)          JBT
owns all right, title and interest in, or possesses enforceable rights to use, all patents, patent applications, trademarks, service
marks, copyrights, rights, licenses, franchises, trade secrets, confidential information, processes and formulations necessary
for the conduct of its business as now conducted (collectively, the “Intangibles”). To the knowledge of JBT,
JBT has not infringed upon the rights of others with respect to the Intangibles and, except as disclosed in the Memorandum, JBT
has not received notice that it has or may have infringed or is infringing upon the rights of others with respect to the Intangibles,
or any written notice of conflict with the asserted rights of others with respect to the Intangibles. To the knowledge of JBT,
no others have infringed upon the rights of JBT with respect to the Intangibles. Except as set forth in the Memorandum, none of
JBT’ Intangibles have expired or terminated, or are expected to expire or terminate, within three years from the date of
this Agreement.

 

(l)           JBT
is not a party to any collective bargaining agreement nor does it employ any member of a union. No executive officer of JBT (as
defined in Rule 501(f) of the Act) has notified JBT that such officer intends to leave JBT or otherwise terminate such officer's
employment with JBT. No executive officer of JBT, to the knowledge of JBT, is in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or any other contract or
agreement or any restrictive covenant, and the continued employment of each such executive officer does not subject JBT to any
liability with respect to any of the foregoing matters. JBT is in compliance with all federal, state, local and foreign laws and
regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and
hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to result
in a JBT Material Adverse Effect.

 

(m)         Subsequent
to the respective dates as of which information is given in the Memorandum, JBT has operated its business in the ordinary course
and, except as may otherwise be set forth in the Memorandum, there has been no: (i) JBT Material Adverse Effect; (ii) transaction
otherwise than in the ordinary course of business consistent with past practice; (iii) issuance of any securities (debt or equity)
or any rights to acquire any such securities other than pursuant to equity incentive plans approved by its Board of Directors;
(iv) damage, loss or destruction, whether or not covered by insurance, with respect to any asset or property of JBT; or (v) agreement
to permit any of the foregoing.

 

(n)          Except
as set forth in the Memorandum, there are no actions, suits, claims, hearings or proceedings pending before any court or governmental
authority or, to the knowledge of JBT, threatened, against JBT, or involving its assets or any of its officers or directors (in
their capacity as such) which, if determined adversely to JBT or such officer or director, could reasonably be expected to have
an JBT Material Adverse Effect or adversely affect the transactions contemplated by this Agreement or the Merger Agreement (as
hereinafter defined) or the enforceability thereof.

 

    	7

    	 

    

  

(o)          JBT
is not: (i) in violation of its Certificate of Incorporation or By-laws; (ii) in default of any indenture, mortgage, deed of trust,
note or other agreement or instrument to which JBT is a party or by which it is or may be bound or to which any of its assets may
be subject, the default of which could reasonably be expected to have an JBT Material Adverse Effect; (iii) in violation of any
statute, rule or regulation applicable to JBT, the violation of which would have an JBT Material Adverse Effect; or (iv) in violation
of any judgment, decree or order of any court or governmental body having jurisdiction over JBT and specifically naming JBT, which
violation or violations individually, or in the aggregate, could reasonably be expected to have an JBT Material Adverse Effect.

 

(p)          Except
as disclosed in the Memorandum, as of the date of this Agreement, no current or former stockholder, director, officer or employee
of JBT, nor, to the knowledge of JBT, any affiliate of any such person is presently, directly or indirectly through his affiliation
with any other person or entity, a party to any loan from JBT or any other transaction (other than as an employee) with JBT providing
for the furnishing of services by, or rental of any personal property from, or otherwise requiring cash payments to any such person.

 

(q)          Except
as disclosed in the Memorandum, JBT has filed, on a timely basis, each federal, state, local and foreign tax return, report and
declarations that were required to be filed, or has requested an extension therefor and has paid all taxes and all related assessments,
charges, penalties and interest to the extent that the same have become due. There are no unpaid taxes in any material amount claimed
to be due by the taxing authority of any jurisdiction, and the officers of JBT know of no basis for any such claim. JBT has not
executed a waiver with respect to the statute of limitations relating to the assessment or collection of any foreign, federal,
state or local tax. To JBT’ knowledge, none of JBT’ tax returns is presently being audited by any taxing authority.
No liens have been filed and no claims are being asserted by or against JBT with respect to any taxes (other than liens for taxes
not yet due and payable). JBT has not received notice of assessment or proposed assessment of any taxes claimed to be owed by it
or any other Person on its behalf. JBT is not a party to any tax sharing or tax indemnity agreement or any other agreement of a
similar nature that remains in effect. JBT has complied in all material respects with all applicable legal requirements relating
to the payment and withholding of taxes and, within the time and in the manner prescribed by law, has withheld from wages, fees
and other payments and paid over to the proper governmental or regulatory authorities all amounts required.

 

(r)           Neither
JBT, nor any director, officer, agent, employee or other Person acting on behalf of JBT has, in the course of its actions for,
or on behalf of, JBT (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses
relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official
or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act
of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to
any foreign or domestic government official or employee.

 

    	8

    	 

    

  

(s)          JBT
is not obligated to pay, and has not obligated the Placement Agent to pay, a finder’s or origination fee in connection with
the Offering (other than to the Placement Agent), and hereby agrees to indemnify the Placement Agent from any such claim made by
any other person, as more fully set forth in Section 8 hereof. JBT has not offered for sale or solicited offers to purchase the
Units except for negotiations with the Placement Agent. Notwithstanding the foregoing, JBT has informed the Placement Agent that
JBT is obligated, pursuant to an agreement dated June 18, 2013, to pay certain cash and warrant compensation to Sunrise Securities
Corp. to the extent any persons/entities set forth on Exhibit A hereto participate in the Offering (the “Sunrise Obligation”);
the foregoing obligation shall not affect the Issuer’s obligation to pay the Agent Compensation (as defined below) to the
Placement Agent hereunder.  

 

(t)           Until
the earlier of (i) the Termination Date and (ii) the Final Closing (as hereinafter defined), JBT will not issue any press release,
grant any interview, or otherwise communicate with the media in any manner whatsoever with respect to the Offering without the
Placement Agent’s prior consent, which consent will not unreasonably be withheld, delayed or conditioned.

 

(u)          No Disqualification Events. None of JBT, any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of JBT participating in the Offering, any beneficial owner of 20% or more of JBT’s outstanding voting equity
securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities
Act) connected with JBT in any capacity at the time of sale of the securities in the Offering (each, a "JBT Covered Person"
and, together, "JBT Covered Persons") is subject to any of the "Bad Actor" disqualifications described
in Rule 506(d)(1)(i) to (viii) under the Securities Act (a "Disqualification Event”). JBT has exercised reasonable
care to determine whether any JBT Covered Person is subject to a Disqualification Event. JBT has complied, to the extent applicable,
with its disclosure obligations under Rule 506(e), and has furnished to the Placement Agent a copy of any disclosures provided
thereunder.

 

(v)         Other
Covered Persons. Except as set forth in Section 2(s), JBT is not aware of any person (other than a Placement Agent Covered
Person (as defined below)) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in
connection with the sale of any the Units.

 

(w)         Notice of Disqualification Events. JBT will promptly notify the Placement Agent in writing of (i) any Disqualification Event
relating to any JBT Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating
to any JBT Covered Person.

 

(x)          Incorporation
by Reference. For the benefit of the Placement Agent, JBT hereby incorporates by reference all of the representations and warranties
contained in Article III, and its covenants contained in Article V, of that certain Agreement and Plan of Merger and Reorganization
to be entered into prior to the Closing by and among Issuer, JBT and JBT Merger Sub, Inc. (the “Merger Agreement”),
in each case with the same force and effect as if specifically set forth herein.

 

    	9

    	 

    

  

(y)          Disclosure.
No representation or warranty contained in Section 2 of this Agreement contains any untrue statement of a material fact or omits
to state a material fact necessary to make the statements herein not misleading in the context of such representations and warranties.

 

2A.         Representations,
Warranties and Covenants of Issuer. The representations and warranties of Issuer (as used in this Section 2A, “Issuer”
refers to Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries) to the Placement Agent contained in this Section 2A are true
and correct as of the date of this Agreement.

 

(a)          The
Memorandum has been prepared in conformity with all applicable laws, and is in compliance in all material respects with Regulation
D, the Act and the requirements of all other Regulations of the SEC relating to offerings of the type contemplated by the Offering,
and the applicable securities laws and the rules and regulations of those jurisdictions wherein the Placement Agent notifies Issuer
that the Units are to be offered and sold excluding any foreign jurisdictions. The Units will be offered and sold pursuant to
the registration exemptions provided by Regulation D and Section 4(a)(2) of the Act as a transaction not involving a public offering
and the requirements of any other applicable state securities laws and the respective rules and regulations thereunder in those
United States jurisdictions in which the Placement Agent notifies Issuer that the Units are being offered for sale. None of Issuer,
its affiliates, or any person acting on its or their behalf (other than the Placement Agent, its affiliates or any person acting
on its behalf, in respect of which no representation is made) has taken nor will it take any action that conflicts with the conditions
and requirements of, or that would make unavailable with respect to the Offering, the exemption(s) from registration available
pursuant to Rule 506(b) of Regulation D or Section 4(a)(2) of the Act, or knows
of any reason why any such exemption would be otherwise unavailable to it. None of Issuer, its predecessors or affiliates has
been subject to any order, judgment or decree of any court of competent jurisdiction temporarily, preliminarily or permanently
enjoining such person for failing to comply with Section 503 of Regulation D. Except for issuances of securities of Issuer to
its founders, Issuer has not, for a period of six months prior to the commencement of the offering of Units, sold, offered for
sale or solicited any offer to buy any of its securities in a manner that would be integrated with the offer and sale of the Units
pursuant to this Agreement, would cause the exemption from registration set forth in Rule 506(b) of Regulation D to become unavailable
with respect to the offer and sale of the Units pursuant to this Agreement in the United States.

 

(b)          Issuer
is duly organized and validly existing in good standing under the laws of the jurisdiction in which it was formed, and has the
requisite power and authority to own its properties and to carry on its business as now being conducted. Issuer is not a participant
in any joint venture, partnership or similar arrangement and does not directly or indirectly own any subsidiaries or otherwise
own or hold capital stock or an equity or similar interest in any entity. Issuer is duly qualified as a foreign entity to do business
and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it
makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have
a Issuer Material Adverse Effect. As used in this Agreement, “Issuer Material Adverse Effect” means any
material adverse effect on the business, properties, assets, operations, results of operations or condition (financial or otherwise)
of Issuer, taken as a whole, or on the transactions contemplated hereby and the other Issuer Transaction Documents (as defined
below) or by the agreements and instruments to be entered into in connection herewith or therewith, or on the authority or ability
of Issuer to perform its obligations under the Issuer Transaction Documents (as defined below).

 

    	10

    	 

    

  

(c)          As
to Issuer only, the Memorandum does not include any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading: provided, however, the foregoing does not apply to any statements or omissions made solely in reliance
on and in conformity with written information furnished to Issuer by JBT or the Placement Agent specifically for use in the preparation
thereof. To the knowledge of Issuer, none of the statements, documents, certificates or other items made, prepared or supplied
by Issuer with respect to the transactions contemplated hereby contains an untrue statement of a material fact or omits to state
a material fact necessary to make the statements contained therein not misleading in light of the circumstances in which they were
made. There is no fact which Issuer has not disclosed in the Memorandum and of which Issuer is aware that materially adversely
affects or that could reasonably be expected to have a Issuer Material Adverse Effect. Notwithstanding anything to the contrary
herein, Issuer makes no representation or warranty with respect to any estimates, projections and other forecasts and plans (including
the reasonableness of the assumptions underlying such estimates, projections and other forecasts and plans) that may have been
delivered to the Placement Agent or its representatives by Issuer, except that such estimates, projections and other forecasts
and plans have been prepared in good faith on the basis of assumptions stated therein, which assumptions were believed to be reasonable
at the time of such preparation.

 

(d)          Issuer
has all requisite corporate power and authority to conduct its business as presently conducted and as proposed to be conducted
(as described in the Memorandum), to enter into and perform its obligations under this Agreement, the Subscription Agreement, the
Registration Rights Agreement, and the other agreements contemplated hereby (this Agreement, the Subscription Agreement, the Registration
Rights Agreement and the other agreements contemplated hereby that Issuer is executing and delivering hereunder are collectively
referred to herein as the “Issuer Transaction Documents”) and subject to necessary Board and stockholder approvals,
to issue, sell and deliver the Units, the shares of Common Stock underlying the Units, and the shares of Common Stock issuable
upon exercise of the Warrants (the “Warrant Shares”), the Agent Warrants (as defined in Section 3(b)) and the
Agent Warrant Shares (as defined in Section 3(b)). Prior to the First Closing, each of the Issuer Transaction Documents will have
been duly authorized. This Agreement has been duly authorized, executed and delivered and constitutes, and each of the other Issuer
Transaction Documents, upon due execution and delivery, will constitute, valid and binding obligations of Issuer, enforceable against
Issuer in accordance with their respective terms (i) except as enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in effect related to laws affecting creditors’ rights generally,
including the effect of statutory and other laws regarding fraudulent conveyances and preferential transfers, and except that no
representation is made herein regarding the enforceability of Issuer’s obligations to provide indemnification and contribution
remedies under the securities laws and (ii) subject to the limitations imposed by general equitable principles (regardless of whether
such enforceability is considered in a proceeding at law or in equity).

 

    	11

    	 

    

  

(e)          None
of the execution and delivery of, or performance by Issuer under this Agreement or any of the other Issuer Transaction Documents
or the consummation of the transactions herein or therein contemplated conflicts with or violates, or will result in the creation
or imposition of, any lien, charge or other encumbrance upon any of the assets of Issuer under any agreement or other instrument
to which Issuer is a party or by which Issuer or its assets may be bound, or any term of the certificate of incorporation or by-laws
of Issuer, or any license, permit, judgment, decree, order, statute, rule or regulation applicable to Issuer or any of its assets,
except in the case of a conflict, violation, lien, charge or other encumbrance (except with respect to Issuer’s certificate
of incorporation or by-laws) which would not, or could not reasonably be expected to, have a Issuer Material Adverse Effect.

 

(f)          As
of the date of the First Closing, Issuer will have the authorized and outstanding capital stock as set forth under the heading
“Capitalization” in the Memorandum. All outstanding shares of capital stock of Issuer are duly authorized, validly
issued and outstanding, fully paid and nonassessable. Except as described in the Memorandum, as of the date of the First Closing:
(i) there will be no outstanding options, stock subscription agreements, warrants or other rights permitting or requiring Issuer
or others to purchase or acquire any shares of capital stock or other equity securities of Issuer or to pay any dividend or make
any other distribution in respect thereof; (ii) there will be no securities issued or outstanding which are convertible into or
exchangeable for any of the foregoing and there are no contracts, commitments or understandings, whether or not in writing, to
issue or grant any such option, warrant, right or convertible or exchangeable security; (iii) no shares of stock or other securities
of Issuer are reserved for issuance for any purpose; (iv) there will be no voting trusts or other contracts, commitments, understandings,
arrangements or restrictions of any kind with respect to the ownership, voting or transfer of shares of stock or other securities
of Issuer, including, without limitation, any preemptive rights, rights of first refusal, proxies or similar rights, and (v) no
person holds a right to require Issuer to register any securities of Issuer under the Act or to participate in any such registration.
As of the date of the First Closing, the issued and outstanding shares of capital stock of Issuer will conform in all material
respects to all statements in relation thereto contained in the Memorandum and the Memorandum describes all material terms and
conditions thereof. All issuances by Issuer of its securities have been, at the times of their issuance, exempt from registration
under the Act and any applicable state securities laws.

 

(g)          Immediately
prior to the First Closing, the shares of Common Stock underlying the Units, the Warrants, the Warrant Shares, the Agent Warrants
and the Agent Warrant Shares will have been duly authorized and, when issued and delivered against payment therefor as provided
in the Issuer Transaction Documents, will be validly issued, fully paid and nonassessable. No holder of any of the shares of Common
Stock underlying the Units, the Warrants, the Warrant Shares, the Agent Warrants or the Agent Warrant Shares will be subject to
personal liability solely by reason of being such a holder, and except as described in the Memorandum, none of the shares of Common
Stock underlying the Units, the Warrants, the Warrant Shares, the Agent Warrants or the Agent Warrant Shares are subject
to preemptive or similar rights of any stockholder or security holder of Issuer or an adjustment under the antidilution or exercise
rights of any holders of any outstanding shares of capital stock, options, warrants or other rights to acquire any securities of
Issuer. Immediately prior to the First Closing, a sufficient number of authorized but unissued shares of Common Stock will have
been reserved for issuance upon the exercise of the Warrants and the Agent Warrants.

 

    	12

    	 

    

  

(h)          No
consent, authorization or filing of or with any court or governmental authority is required in connection with the issuance or
the consummation of the transactions contemplated herein or in the other Issuer Transaction Documents, except for required filings
with the SEC and the applicable state securities commissions relating specifically to the Offering (all of which filings will be
duly made by, or on behalf of, Issuer), other than those which are required to be made after the First Closing (all of which will
be duly made on a timely basis).

 

(i)           Subsequent
to the respective dates as of which information is given in the Memorandum, Issuer has operated its business in the ordinary course
and, except as may otherwise be set forth in the Memorandum, there has been no: (i) Issuer Material Adverse Effect; (ii) transaction
otherwise than in the ordinary course of business consistent with past practice; (iii) issuance of any securities (debt or equity)
or any rights to acquire any such securities other than pursuant to equity incentive plans approved by its Board of Directors;
(iv) damage, loss or destruction, whether or not covered by insurance, with respect to any asset or property of Issuer; or (v)
agreement to permit any of the foregoing.

 

(j)           Except
as set forth in the Memorandum, there are no actions, suits, claims, hearings or proceedings pending before any court or governmental
authority or, to the knowledge of Issuer, threatened, against Issuer, or involving its assets or any of its officers or directors
(in their capacity as such) which, if determined adversely to Issuer or such officer or director, could not reasonably be expected
to have a Issuer Material Adverse Effect or adversely affect the transactions contemplated by this Agreement or the Merger Agreement
or the enforceability thereof.

 

(k)          Issuer
is not obligated to pay, and has not obligated the Placement Agent to pay, a finder’s or origination fee in connection with
the Offering (other than to the Placement Agent), and hereby agrees to indemnify the Placement Agent from any such claim made by
any other person, as more fully set forth in Section 8 hereof. Issuer has not offered for sale or solicited offers to purchase
the Units except for negotiations with the Placement Agent. Except as set forth in the Memorandum, no other person has any right
to participate in any offer, sale or distribution of Issuer’s securities to which the Placement Agent’s rights, described
herein, shall apply. Notwithstanding the foregoing, Placement Agent has been advised about the Sunrise Obligation; the foregoing
obligation shall not affect the Issuer’s obligation to pay the Agent Compensation to the Placement Agent hereunder.

 

(l)           Neither
the sale of the Units by Issuer nor its use of the proceeds thereof will violate the Trading with the Enemy Act, as amended, or
any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended)
or any enabling legislation or executive order relating thereto. Without limiting the foregoing, Issuer is not (a) a person whose
property or interests in property are blocked pursuant to Section 1 of Executive Order 13224 of September 23, 2001 Blocking Property
and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism (66 Fed. Reg. 49079 (2001)) or (b)
a person who engages in any dealings or transactions, or be otherwise associated, with any such person. Issuer and its subsidiaries,
if any, are in compliance, in all material respects, with the USA Patriot Act of 2001 (signed into law October 26, 2001).

 

    	13

    	 

    

  

(m)         Until
the earlier of (i) the Termination Date and (ii) the Final Closing (as hereinafter defined), Issuer will not issue any press release,
grant any interview, or otherwise communicate with the media in any manner whatsoever with respect to the Offering without the
Placement Agent’s prior consent, which consent will not unreasonably be withheld, delayed or conditioned.

 

(n)          Issuer
is in the process of establishing internal accounting controls sufficient to provide reasonable assurances that (i) transactions
are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability
for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and
(iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is
taken with respect to any differences.

 

(o)          Issuer
is in the process of establishing “disclosure controls and procedures” (as such term is defined in Rule 13a-15(e) and
15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)), which (i) are designed to ensure
that material information relating to Issuer is made known to Issuer’s principal executive officer and its principal financial
officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange
Act are being prepared, and (ii) such disclosure controls and procedures are effective to perform the functions for which they
were established. Issuer is not aware of any fraud, whether or not material, that involves management or other employees who have
a role in Issuer’s internal controls.

 

(p)          No
Disqualification Events. None of Issuer, any of its predecessors, any affiliated issuer, any director, executive officer, other
officer of Issuer participating in the Offering, any beneficial owner of 20% or more of Issuer’s outstanding voting equity
securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities
Act) connected with Issuer in any capacity at the time of sale of the securities in this Offering (each, an "Issuer Covered
Person" and, together, "Issuer Covered Persons") is subject to any of the "Bad Actor" disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a "Disqualification Event”). Issuer has exercised
reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. Issuer has complied, to
the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Placement Agent a copy of any
disclosures provided thereunder.  

 

(q)          Other
Covered Persons. Except as set forth in Section 2(s), Issuer is not aware of any person (other than any Placement Agent Covered
Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the
sale of any the Units.

 

    	14

    	 

    

  

(r)           Notice
of Disqualification Events. Issuer will promptly notify the Placement Agent in writing of (i) any Disqualification Event relating
to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating
to any Issuer Covered Person.

 

(s)          Incorporation
by Reference. For the benefit of the Placement Agent, Issuer hereby incorporates by reference all of the representations and
warranties contained in Article IV, and its covenants contained in Article V, of the Merger Agreement, in each case with the same
force and effect as if specifically set forth herein.

 

(t)          Disclosure.
No representation or warranty contained in Section 2A of this Agreement contains any untrue statement of a material fact or omits
to state a material fact necessary to make the statements herein not misleading in the context of such representations and warranties.

 

2B.         Representations,
Warranties and Covenants of Placement Agent. The Placement Agent hereby represents and warrants to JBT and Issuer that the
following representations and warranties are true and correct as of the date of this Agreement:

 

(a)          The
Placement Agent is a corporation duly organized, validly existing and in good standing under the laws of the State of New York
and has all requisite corporate power and authority to enter into this Agreement and to carry out and perform its obligations under
the terms of this Agreement.

 

(b)          This
Agreement has been duly authorized, executed and delivered by the Placement Agent, and upon due execution and delivery by JBT and
Issuer, this Agreement will be a valid and binding agreement of the Placement Agent enforceable against it in accordance with its
terms, except as may be limited by principles of public policy and, as to enforceability, subject to applicable bankruptcy, insolvency,
reorganization, moratorium and similar laws relating to or affecting creditor’s rights from time to time in effect and subject
to general equity principles.

 

(c)          The
Placement Agent is a member of FINRA and is registered as a broker-dealer under the Exchange Act, and under the securities acts
of each state into which it is making offers or sales of the Units. None of the Placement Agent or its affiliates, or any person
acting on behalf of the foregoing (other than Issuer, JBT, its or their affiliates or any person acting on its or their behalf,
in respect of which no representation is made) has taken nor will it take any action that conflicts with the conditions and requirements
of, or that would make unavailable with respect to the Offering, the exemption(s) from registration available pursuant to Rule
506 of Regulation D or Section 4(a)(2) of the Act, or knows of any reason why any such exemption would be otherwise unavailable
to it.

 

(d)  No Disqualification
Events. The Placement Agent represents that neither it, nor to its knowledge any of its directors, executive officers, general
partners, managing members or other officers participating in the Offering (each, a "Placement Agent Covered Person"
and, together, "Placement Agent Covered Persons"), is subject to any Disqualification Event, except for a Disqualification
Event (i) contemplated by Rule 506(d)(2) of the Securities Act and (ii) a description of which has been furnished in writing to
JBT and Issuer prior to the date hereof.

    	15

    	 

    

  

(e)  Other Covered
Persons. The Placement Agent represents that it is not aware of any person (other than any Placement Agent Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale
of any Units. Placement Agent will promptly notify JBT and Issuer of any agreement entered into between such Placement Agent and
such person in connection with such sale.

 

(f)  Notice of Disqualification
Events. The Placement Agent will notify JBT and Issuer promptly in writing of (i) any Disqualification Event relating to any
Placement Agent Covered Person not previously disclosed to the Company in accordance with Section 2B(d), No Disqualification
Events and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Placement Agent
Covered Person.

 

(g)          Disclosure.    As
to Placement Agent only, the Memorandum does not include any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading: provided, however, the foregoing does not apply to any statements or omissions made solely in reliance
on and in conformity with written information furnished to Placement Agent by JBT or Issuer specifically for use in the preparation
thereof.

 

(h)          Litigation.  There
are no actions, suits, claims, hearings or proceedings pending before any court or governmental authority or, to the knowledge
of Placement Agent, threatened, against Placement Agent or involving its assets or to the knowledge of Placement Agent, any of
its officers or directors (in their capacity as such) which, if determined adversely to Placement Agent or such officer or director,
could reasonably be expected to adversely affect Placement Agent’s ability to perform its obligations hereunder.

 

3.           Placement
Agent Compensation.

 

(a)          In
connection with the Offering, the Issuer will pay at each Closing a cash fee (the “Agent Cash Fee”) to the Placement
Agent equal to 10% of the gross proceeds from the sale of the Units consummated at such Closing.

 

(b)          As
additional compensation at each Closing the Issuer will issue to the Placement Agent (or its designee(s)) for nominal consideration,
warrants (the “Agent Warrants;” the Agent Cash Fee and Agent Warrants are sometimes referred to herein collectively
as “Agent Compensation”) to purchase shares of Common Stock (the shares of Common Stock issuable upon exercise
of the Agent Warrants are hereinafter referred to as the “Agent Warrant Shares” and the Agent Warrants and the
Agent Warrant Shares are collectively referred to as the “Agent Securities”). The Agent Warrants shall be exercisable
for that number of shares of Common Stock equaling 10% of the number of shares of Common Stock (i) included in the Units at an
exercise price of $1.00 per share and (ii) issuable upon exercise of the Warrants at an exercise price of $1.00 per share (the
“Agent Warrants”). The Agent’s Warrants shall be exercisable until the date that is five (5) years after
the First Closing, shall contain immediate cashless exercise provisions and shall not be callable by the Company.

 

    	16

    	 

    

  

(c)          At
each Closing, the Issuer will pay the Placement Agent a non-accountable expense allowance equal to 3% of the gross proceeds from
the sale of the Units consummated at such Closing (the “Agent Expense Allowance”). The Placement Agent will
not bear any of Issuer’s or JBT’s respective legal, accounting, printing or other expenses in connection with any transaction
contemplated hereby. The Placement Agent will pay for its own expenses, including its legal fees and expenses, from the Agent Expense
Allowance. The Agent Expense Allowance will be reduced by the $25,000 paid by JBT to the Placement Agent upon the execution and
delivery of the term sheet.

 

(d)          The
Company shall also pay and issue to the Placement Agent the Agent Compensation calculated according to the percentages set forth
in Sections 3(a) and (b) of this Agreement, if any person or entity contacted by the Placement Agent and provided with a Memorandum
during the Offering Period (other than existing shareholders of JBT) and with whom the Placement Agent has discussions regarding
a potential investment in the Offering, invests in the Company (other than through open market purchases or securities purchased
in any underwritten public offering) and irrespective of whether such potential investor purchased Units in the Offering (the “Tail
Investors”) at any time prior to the earlier of the date that is eighteen (18) months after the Termination Date or the
Final Closing, whichever is applicable. The names of Tail Investors shall be provided in writing by the Placement Agent to the
Issuer within 10 days following the Final Closing (the “Tail Investor List”); provided, that such Tail Investor
List shall include persons or entities that actually received a copy of the Memorandum. The Company acknowledges and agrees that
the Tail Investor List is proprietary to the Placement Agent, shall be maintained in strict confidence by the Company and those
persons/entities on such list shall not be contacted by the Company without the Placement Agent’s prior written consent;
provided, however, that such restrictions shall not apply to ordinary course stockholder communications by the Company to its stockholders,
including those Tail Investors that are stockholders of the Company. In the event the Placement Agent exercises its ROFR pursuant
to Section 3(g), the provisions of this Section 3(d) will not be operative with respect to such offering. 

 

(e)          At
the First Closing, the Company and the Placement Agent shall enter into a non-exclusive Finder’s Fee Agreement (the “Finder’s
Agreement”), which will provide that, during the two (2) year period following the later of the Termination Date or the
First Closing, if the Company or any of its affiliates shall enter into any of the transactions enumerated in the Finder’s
Agreement (such transactions to include business combinations with the Company) solely with any party introduced to the Company
by the Placement Agent (but not with respect to any party with which the Company (i) has previously been introduced to by a party
other than Placement Agent or (ii) has already commenced discussions with), then the Company shall pay or cause to be paid to the
Placement Agent a cash finder’s fee (the “Finder’s Fee”) payable in cash at the closing of such
transaction, equal to 5% of the first $1 million of consideration paid by or to the Company, plus 4% of the next $1 million of
consideration paid by or to the Company, plus 3% of the next $5 million of the consideration paid by or to the Company, plus 2.5%
of any consideration paid by or to the Company in excess of $7 million; provided, however, that the Placement Agent will not be
entitled to a finder's fee entered into with any party with whom the Company had a pre-existing relationship prior to the date
of the specific introduction. An initial list of parties will be agreed to between the Company and the Placement Agent prior to
the execution of the Finder’s Agreement, which list will be updated from time to time for any new introductions that are
made following the Closing and such list shall be deemed parties introduced to the Company by the Placement Agent.

 

    	17

    	 

    

  

(f)           In
the event the Issuer elects to redeem the Warrants pursuant to the provisions thereto, the Placement Agent will be engaged as exclusive
warrant solicitation agent at least 20 calendar days prior to the time notice of redemption is delivered to holders of Warrants.
The engagement letter will provide for the payment to the Placement Agent of, inter alia, a cash fee of 5% of the net cash proceeds
from the exercise of each Warrant exercised by a Warrant holder that has been solicited by the Placement Agent following a redemption
notice.

 

(g)          Effective
as of the First Closing, the Company hereby grants to the Placement Agent, for a period of twelve (12) months following the Final
Closing (the “ROFR Term”), the irrevocable preferential right of first refusal to act as lead placement agent
or underwriter for any proposed private placement or public offering of the Company’s securities (equity or debt, but excluding
any institutional bank debt and any securities sold directly to investors). In that regard, it is understood that if the Company
determines to pursue a financing during the ROFR Term in which a third party placement agent or underwriter will be engaged, the
Company shall promptly provide the Placement Agent with a written notice of such intention and statement of terms (the “Notice”).
If, within seven (7) business days of the receipt of the Notice, the Placement Agent does not accept in writing such offer to act
as lead placement agent or underwriter with respect to such offering upon the terms proposed, then the Company shall be entitled
to engage a placement agent or underwriter other than the Placement Agent; provided that the terms of the compensation to be paid
to such other placement agent or underwriter are not materially less favorable to the Company than the terms included in the Notice.
The Placement Agent’s failure to exercise these preferential rights in any situation shall not affect its preferential rights
to any subsequent offering during the ROFR Term. Each of JBT and the Issuer represent and warrant that no other person has any
right to participate in any offer, sale or distribution of JBT’s or the Issuer’s securities to which the Placement
Agent’s preferential rights shall apply.

 

(h)          For
a period of two (2) years from the First Closing, the Issuer hereby grants the Placement Agent the right to appoint one (1) member
of the Issuer’s board of directors (the “Aegis Director”). The initial Aegis Director shall be David Hochman,
who shall be appointed to the Board of Directors at the First Closing, with any successor Aegis Director chosen by the Placement
Agent to be subject to the reasonable approval of the Issuer. The Aegis Director shall be entitled to the same indemnification
and director compensation (if any) as any other director of the Issuer and shall be subject to removal on the same terms as any
other director of the Issuer.

 

(i)           The
provisions of Sections 3(d), 3(g) and 3(h) of this Agreement shall terminate immediately upon the termination of Adam Stern’s
or Ramnarain Jaigobind’s employment with the Placement Agent or the Placement Agent ceases to do business as Aegis Capital
Corp.

 

    	18

    	 

    

  

4.           Subscription
and Closing Procedures.

 

(a)          JBT
and Issuer shall cause to be delivered to the Placement Agent copies of the Memorandum and have each consented, and hereby consent,
to the use of such copies for the purposes permitted by the Act and applicable securities laws and in accordance with the terms
and conditions of this Agreement, and hereby each authorize the Placement Agent and its agents and employees to use the Memorandum
in connection with the sale of the Units until the earlier of (i) the Termination Date or (ii) the Final Closing, and no person
or entity is or will be authorized to give any information or make any representations other than those contained in the Memorandum
or to use any offering materials other than those contained in the Memorandum in connection with the sale of the Units.

 

(b)          JBT
and Issuer shall make available to the Placement Agent and its representatives such information as may be reasonably requested
in making a reasonable investigation of JBT and Issuer and their respective affairs and shall provide access to such employees
during normal business hours as shall be reasonably requested by the Placement Agent.

 

(c)          Each
prospective purchaser will be required to complete and execute an original omnibus signature page, for each of the Subscription
Agreement and the Registration Rights Agreement (the “Subscription Documents”), which will be forwarded
or delivered to the Placement Agent at the Placement Agent’s offices at the address set forth in Section 12 hereof, together
with the subscriber’s wire transfer in the full amount of the purchase price for the number of Units desired to be purchased,
subject to the Placement Agent’s right to accept a check in lieu of a wire transfer.

 

(d)          All
funds for subscriptions received from the Offering will be promptly forwarded by the Placement Agent and deposited into a non-interest
bearing escrow account (the “Escrow Account”) established for such purpose with Signature Bank (the “Escrow
Agent”). All such funds for subscriptions will be held in the Escrow Account pursuant to the terms of an escrow agreement
among Issuer, JBT, the Placement Agent and the Escrow Agent. The Company will pay all fees related to the establishment
and maintenance of the Escrow Account. Subject to the receipt of subscriptions for the Minimum Amount, the Company will either
accept or reject, for any or no reason, the Subscription Documents in a timely fashion and at each Closing Issuer and JBT will
countersign the Subscription Documents and provide duplicate copies of such documents to the Placement Agent for distribution to
the subscribers. The Company, or the Placement Agent on the Company’s behalf, will promptly return to subscribers incomplete,
improperly completed, improperly executed and rejected subscriptions and give written notice thereof to the Placement Agent upon
such return.

 

    	19

    	 

    

  

(e)          If
subscriptions for at least the Minimum Amount have been accepted prior to the Termination Date, the funds therefor have been collected
by the Escrow Agent and all of the conditions set forth elsewhere in this Agreement are fulfilled, a closing shall be held promptly
with respect to Units sold (the “First Closing”). Thereafter remaining Units will continue to be offered and
sold until the Termination Date and additional closings (each a “Closing”) may from time to time be conducted
at times mutually agreed to between the Placement Agent and the Company with respect to additional Units sold, with the final closing
(“Final Closing”) to occur within 10 days after the earlier of the Termination Date and the date on which the
all Units has been fully subscribed for. Delivery of payment for the accepted subscriptions for Units from funds held in the Escrow
Account will be made at each Closing against delivery of the Shares and Warrants by the Company. Executed certificates for the
Common Stock, Warrants and the Placement Agent Warrants will be in such authorized denominations and, with respect to investors
located by the Placement Agent, will be registered in such names as the Placement Agent may request and will be made available
to the Placement Agent for checking and packaging at the Placement Agent’s office at each Closing or within ten (10) business
days following a Closing.

 

(f)          If
Subscription Documents for the Minimum Amount have not been received and accepted by the Company on or before the Termination Date
for any reason, the Offering will be terminated, no Units will be sold, and the Escrow Agent will, at the request of the Placement
Agent, cause all monies received from subscribers for the Units to be promptly returned to such subscribers without interest, penalty,
expense or deduction.

 

5.           Further
Covenants. JBT and Issuer hereby covenant and agree that:

 

(a)          Except
upon prior written notice to the Placement Agent, neither JBT nor Issuer shall, at any time prior to the Final Closing, knowingly
take any action which would cause any of the representations and warranties made by it in this Agreement not to be complete and
correct in all material respects on and as of each Closing Date with the same force and effect as if such representations and warranties
had been made on and as of each such date (except to the extent any representation or warranty relates to an earlier date).

 

(b)          If,
at any time prior to the Final Closing, any event shall occur that causes (i) a JBT Material Adverse Effect or (ii) a Issuer Material
Adverse Effect, either of which as a result it becomes necessary to amend or supplement the Memorandum so that the representations
and warranties herein remain true and correct in all material respects, or in case it shall be necessary to amend or supplement
the Memorandum to comply with Regulation D or any other applicable securities laws or regulations, either JBT or Issuer, as applicable,
will promptly notify the Placement Agent and shall, at its sole cost, prepare and furnish to the Placement Agent copies of appropriate
amendments and/or supplements in such quantities as the Placement Agent may reasonably request. Neither JBT nor Issuer will at
any time before the Final Closing prepare or use any amendment or supplement to the Memorandum of which the Placement Agent will
not previously have been advised and furnished with a copy, or which is not in compliance in all material respects with the Act
and other applicable securities laws. As soon as JBT or Issuer is advised thereof, JBT or Issuer, as applicable, will advise the
Placement Agent and its counsel, and confirm the advice in writing, of any order preventing or suspending the use of the Memorandum,
or the suspension of any exemption for such qualification or registration thereof for offering in any jurisdiction, or of the institution
or threatened institution of any proceedings for any of such purposes, and JBT and Issuer, as applicable, will use their reasonable
best efforts to prevent the issuance of any such order and, if issued, to obtain as soon as reasonably possible the lifting thereof.

 

    	20

    	 

    

  

(c)          JBT
and Issuer shall comply with the Act, the Exchange Act and the rules and regulations thereunder, all applicable state securities
laws and the rules and regulations thereunder in the states in which Placement Agent's Blue Sky counsel has advised the Placement
Agent, JBT and/or Issuer that the Units are qualified or registered for sale or exempt from such qualification or registration,
so as to permit the continuance of the sales of the Units, and will file or cause to be filed with the SEC, and shall promptly
thereafter forward or cause to be forwarded to the Placement Agent, any and all reports on Form D as are required.

 

(d)          Issuer
shall use best efforts to qualify the Units for sale under the securities laws of such jurisdictions in the United States as may
be mutually agreed to by JBT, Issuer and the Placement Agent, and Issuer will make or cause to be made such applications and furnish
information as may be required for such purposes, provided that Issuer will not be required to qualify as a foreign corporation
in any jurisdiction or execute a general consent to service of process. Issuer will, from time to time, prepare and file such statements
and reports as are or may be required to continue such qualifications in effect for so long a period as the Placement Agent may
reasonably request with respect to the Offering.

 

(e)          The
Issuer shall place a legend on the certificates representing the Shares, Warrants and the Agent Warrants that the securities evidenced
thereby have not been registered under the Act or applicable state securities laws, setting forth or referring to the applicable
restrictions on transferability and sale of such securities under the Act and applicable state laws.

 

(f)          The
Company shall apply the net proceeds from the sale of the Units for the purposes substantially as described under the “Use
of Proceeds” section of the Memorandum. Except as set forth in the Memorandum, the Company shall not use any of the net proceeds
of the Offering to repay indebtedness to officers (other than accrued salaries incurred in the ordinary course of business), directors
or stockholders of the Company without the prior written consent of the Placement Agent.

 

(g)          During
the Offering Period, JBT or Issuer, as applicable, shall afford each prospective purchaser of Units the opportunity to ask questions
of and receive answers from an officer of JBT or Issuer concerning the terms and conditions of the Offering and the opportunity
to obtain such other additional information necessary to verify the accuracy of the Memorandum to the extent JBT or Issuer possesses
such information or can acquire it without unreasonable expense.

 

(h)          Except
with the prior written consent of the Placement Agent, JBT and Issuer shall not, at any time prior to the earlier of the Final
Closing or the Termination Date, except as contemplated by the Memorandum (i) engage in or commit to engage in any transaction
outside the ordinary course of business as described in the Memorandum, (ii) issue, agree to issue or set aside for issuance any
securities (debt or equity) or any rights to acquire any such securities, (iii) incur, outside the ordinary course of business,
any material indebtedness, (iv) dispose of any material assets, (v) make any acquisition or (vi) change its business or operations.

 

    	21

    	 

    

  

(i)           The
Company shall pay all reasonable expenses incurred in connection with the preparation and printing of all necessary offering documents
and instruments related to the Offering and the issuance of the Shares, the Warrants and the Agent Warrants and will also pay the
Company's own expenses for accounting fees, legal fees and other costs involved with the Offering. The Company will provide at
its own expense such quantities of the Memorandum and other documents and instruments relating to the Offering as the Placement
Agent may reasonably request. All Blue Sky filings related to this Offering shall be prepared by JBT’s counsel at
the Company’s expense, with copies of all filings to be promptly forwarded to the Placement Agent. Further, as promptly as
practicable after the Final Closing, the Company shall prepare, at its own expense, velobound "closing binders" relating
to the Offering and will distribute one such binder to each of the Placement Agent and its counsel.

 

(j)          Until
the earlier of the Termination Date or the Final Closing, neither JBT nor Issuer nor any person or entity acting on such persons’
behalf will negotiate with any other placement agent or underwriter with respect to a private or public offering of such entity’s
debt or equity securities. Neither JBT nor Issuer nor anyone acting on such persons’ behalf will, until the earlier of the
Termination Date or the Final Closing, without the prior written consent of the Placement Agent, offer for sale to, or solicit
offers to subscribe for Shares from, or otherwise approach or negotiate in respect thereof with, any other person.

 

6.           Conditions
of Placement Agent’s Obligations. The obligations of the Placement Agent hereunder to effect a Closing are subject to
the fulfillment, at or before each Closing, of the following additional conditions:

 

(a)          Each
of the representations and warranties made by JBT and Issuer qualified as to materiality shall be true and correct at all times
prior to and on each Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date,
in which case such representation or warranty shall be true and correct as of such earlier date, and the representations and warranties
made by JBT and Issuer not qualified as to materiality shall be true and correct in all material respects at all times prior to
and on each Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which
case such representation or warranty shall be true and correct in all material respects as of such earlier date.

 

(b)          JBT
and Issuer shall have performed and complied in all material respects with all agreements, covenants and conditions required to
be performed and complied with by it at or before the Closing.

 

(c)          The
Memorandum did not, and as of the date of any amendment or supplement thereto will not, include any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading.

 

(d)          No
order suspending the use of the Memorandum or enjoining the Offering or sale of the Units shall have been issued, and no proceedings
for that purpose or a similar purpose shall have been initiated or pending, or, to the best of JBT’ and Issuer’s knowledge,
be contemplated or threatened.

 

    	22

    	 

    

   

(e)          (e)          The
Placement Agent shall have received a certificate of the Chief Executive Officer of each of JBT and Issuer, dated as of the Closing
Date, certifying, as to the fulfillment of the conditions set forth in subparagraphs (a), (b), (c) and (d) above.

 

(f)           JBT
and Issuer shall have delivered to the Placement Agent: (i) a certified charter document and good standing certificate, each dated
as of a date within 10 days prior to the Closing Date from the secretary of state of its jurisdiction of incorporation; and (ii)
resolutions of JBT's and Issuer's Board of Directors approving this Agreement and the transactions and agreements contemplated
by this Agreement, the Merger Agreement and the Memorandum, certified by the Chief Executive Officer of JBT and Issuer, and (iii)
resolutions of JBT's, Issuer’s and Corbus Pharmaceuticals Acquisition, Inc.’s Board of Directors and shareholders approving
the Merger Agreement and the transactions and agreements contemplated by the Merger Agreement.

 

(g)          At
each Closing, the Company shall pay and/or issue to the Placement Agent the Agent Compensation and Agent Expense Allowance earned
in such Closing.

 

(h)          At
the First Closing, (i) JBT shall deliver to the Placement Agent a signed opinion of Lowenstein Sandler LLP, counsel to JBT,
dated as of the Closing Date, substantially in the form annexed hereto as Exhibit B-1 and (ii) Issuer shall deliver to the Placement
Agent a signed opinion Meister Seelig & Fein LLP, counsel to Issuer, dated as of the Closing Date, substantially in the form
annexed hereto as Exhibit B-2. At all subsequent Closings, Issuer and JBT shall deliver to the Placement Agent a signed opinion
of Lowenstein Sandler LLP, counsel to Issuer and JBT following the First Closing, dated as of the Closing Date, substantially in
the forms annexed hereto as Exhibit B-1 and B-2.

 

(i)           All
proceedings taken at or prior to the Closing in connection with the authorization, issuance and sale of the Shares, the Warrants
and the Agent Warrants will be reasonably satisfactory in form and substance to the Placement Agent and its counsel, and such counsel
shall have been furnished with all such documents, certificates and opinions as it may reasonably request upon reasonable prior
notice in connection with the transactions contemplated hereby.

 

(j)           The
Merger per the terms of the Merger Agreement shall have been consummated.

 

(k)          Lock-up
agreements with all of JBT’s existing officers and directors and with all of JBT’s and Issuer’s stockholders
who own in the aggregate 5% of the fully-diluted ownership of JBT and/or Issuer prior to the First Closing, in form and substance
reasonably acceptable to the Placement Agent and consistent with the terms set forth in the Memorandum, shall have been executed
and delivered to the Placement Agent1.

 

 

1 The Company would like to
provide Summer’s a carve-out with respect to 100,000 shares that he will receive in the Merger.

 

    	23

    	 

    

  

7.           Conditions
of Issuer’s and JBT’s Obligations. The obligations of Issuer and JBT hereunder to effect a Closing are subject
to the fulfillment, at or before each Closing, of the following additional condition that each of the representations and warranties
made by Placement Agent herein are true and correct as of each Closing Date.

 

8.           Indemnification.

 

(a)          Issuer
and JBT severally if the Merger does not occur, and jointly and severally following the consummation of the Merger, will: (i) indemnify
and hold harmless the Placement Agent, its agents and their respective officers, directors, employees, selected dealers and each
person, if any, who controls the Placement Agent within the meaning of the Section 15 of the Act or Section 20(a) of the Exchange
Act and such selected dealers (each an “Indemnitee” or a "Placement Agent Party") against,
and pay or reimburse each Indemnitee for, any and all losses, claims, damages, liabilities or expenses whatsoever (or actions or
proceedings or investigations in respect thereof), joint or several (which will, for all purposes of this Agreement, include, but
not be limited to, all reasonable costs of defense and investigation and all reasonable attorneys’ fees, including appeals),
to which any Indemnitee may become subject (x) under the Act or otherwise, in connection with the offer and sale of the Units and
(y) as a result of the breach of any representation, warranty or covenant made by either JBT or Issuer herein, regardless of whether
such losses, claims, damages, liabilities or expenses shall result from any claim by any Indemnitee or by any third party; and
(ii) reimburse each Indemnitee for any legal or other expenses reasonably incurred in connection with investigating or defending
against any such loss, claim, action, proceeding or investigation; provided, however, that Issuer and
JBT will not be liable in any such case to the extent that any such claim, damage or liability is finally judicially determined
to have resulted primarily from (A) an untrue statement or alleged untrue statement of a material fact made in the Memorandum,
or an omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, made solely in reliance upon and in conformity with written information furnished to Issuer and/or JBT
by the Placement Agent specifically for use in the Memorandum, (B) any violations by the Placement Agent of the Act or state securities
laws which does not result from a violation thereof by JBT, Issuer, or any of their respective affiliates or (C) the Placement
Agent’s bad faith or gross negligence. In addition to the foregoing agreement to indemnify and reimburse, Issuer and JBT
jointly and severally will indemnify and hold harmless each Indemnitee against any and all losses, claims, damages, liabilities
or expenses whatsoever (or actions or proceedings or investigations in respect thereof), joint or several (which shall, for all
purposes of this Agreement, include, but not be limited to, all reasonable costs of defense and investigation and all reasonable
attorneys' fees, including appeals) to which any Indemnitee may become subject insofar as such costs, expenses, losses, claims,
damages or liabilities arise out of or are based upon the claim of any person or entity that he or it is entitled to broker’s
or finder’s fees from any Indemnitee in connection with the Offering, other than fees due to the Placement Agent. The foregoing
indemnity agreements will be in addition to any liability Issuer and JBT may otherwise have.

 

    	24

    	 

    

  

(b)          The
Placement Agent will indemnify and hold harmless Issuer and JBT, their respective officers, directors, and each person, if any,
who controls such entity Section 15 of the Act or Section 20(a) of the Exchange Act against, and pay or reimburse any such person
for, any and all losses, claims, damages, liabilities or expenses whatsoever (or actions, proceedings or investigations in respect
thereof) to which Issuer or JBT or any such person may become subject under the Act or otherwise, whether such losses, claims,
damages, liabilities or expenses shall result from any claim of Issuer, JBT or any such person who controls Issuer or JBT within
the meaning of the Act or by any third party, but only to the extent that such losses, claims, damages or liabilities results from
(i) any untrue statement or alleged untrue statement of any material fact contained in the Memorandum made in reliance upon and
in conformity with information contained in the Memorandum relating to the Placement Agent, or an omission or alleged omission
to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in either
case, if made or omitted in reliance upon and in conformity with written information furnished to Issuer or JBT by the Placement
Agent, specifically for use in the preparation thereof or (ii) any violations by the Placement Agent of the Act or state securities
laws which does not result from a violation thereof by JBT, Issuer, or any of their respective affiliates. The Placement Agent
will reimburse the Company or any such person for any legal or other expenses reasonably incurred in connection with investigating
or defending against any such loss, claim, damage, liability or action, proceeding or investigation to which such indemnity obligation
applies. The foregoing indemnity agreements are in addition to any liability which the Placement Agent may otherwise have. Notwithstanding
the foregoing, in no event (except in the event of gross negligence or willful misconduct by the Placement Agent to the extent
and only to the extent if found in a final judgment by a court of competent jurisdiction) shall the Placement Agent’s indemnification
obligation hereunder exceed the amount of the Agent’s Cash Fee actually received by it.

 

(c)          Promptly
after receipt by an indemnified party under this Section 8 of notice of the commencement of any action, claim, proceeding or investigation
(the “Action”), such indemnified party, if a claim in respect thereof is to be made against the indemnifying
party under this Section 8, will notify the indemnifying party of the commencement thereof, but the omission to so notify the indemnifying
party will not relieve it from any liability that it may have to any indemnified party under this Section 8 unless the indemnifying
party has been substantially prejudiced by such omission. The indemnifying party will be entitled to participate in and, to the
extent that it may wish, jointly with any other indemnifying party, to assume the defense thereof subject to the provisions herein
stated, with counsel reasonably satisfactory to such indemnified party. The indemnified party will have the right to employ separate
counsel in any such Action and to participate in the defense thereof, but the fees and expenses of such counsel will not be at
the expense of the indemnifying party if the indemnifying party has assumed the defense of the Action with counsel reasonably satisfactory
to the indemnified party, provided, however, that if the indemnified party shall be requested by the indemnifying
party to participate in the defense thereof or shall have concluded in good faith and specifically notified the indemnifying party
either that there may be specific defenses available to it that are different from or additional to those available to the indemnifying
party or that such Action involves or could have a material adverse effect upon it with respect to matters beyond the scope of
the indemnity agreements contained in this Agreement, then the counsel representing it, to the extent made necessary by such defenses,
shall have the right to direct such defenses of such Action on its behalf and in such case the reasonable fees and expenses of
such counsel in connection with any such participation or defenses shall be paid by the indemnifying party. No settlement of any
Action against an indemnified party will be made without the consent of the indemnifying party and the indemnified party, which
consent shall not be unreasonably withheld, delayed or conditioned in light of all factors of importance to such party, and no
indemnifying party shall be liable to indemnify any person for any settlement of any such claim effected without such indemnifying
party’s consent.

 

    	25

    	 

    

  

9.           Contribution.
To provide for just and equitable contribution, if: (i) an indemnified party makes a claim for indemnification pursuant to Section
8 hereof and it is finally determined, by a judgment, order or decree not subject to further appeal that such claims for indemnification
may not be enforced, even though this Agreement expressly provides for indemnification in such case; or (ii) any indemnified or
indemnifying party seeks contribution under the Act, the Exchange Act, or otherwise, then each indemnifying party shall contribute
to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative
benefits but also the relative fault of the Company on the one hand and the Placement Agent on the other in connection with the
statements or omissions which resulted in such losses, claims, damages, liabilities or expenses (or actions in respect thereof),
as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Placement
Agent on the other shall be deemed to be in the same proportion as the total net proceeds from the Offering (before deducting expenses)
received by the Company bear to the total Agent Cash Fees received by the Placement Agent. The relative fault, in the case of an
untrue statement, alleged untrue statement, omission or alleged omission will be determined by, among other things, whether such
statement, alleged statement, omission or alleged omission relates to information supplied by the Company or by the Placement Agent,
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement,
alleged statement, omission or alleged omission. The Company and the Placement Agent agree that it would be unjust and inequitable
if the respective obligations of the Company and the Placement Agent for contribution were determined by pro rata
allocation of the aggregate losses, liabilities, claims, damages and expenses or by any other method or allocation that does not
reflect the equitable considerations referred to in this Section 9. No person guilty of a fraudulent misrepresentation (within
the meaning of Section 10(f) of the Act) will be entitled to contribution from any person who is not guilty of such fraudulent
misrepresentation. For purposes of this Section 9, each person, if any, who controls the Placement Agent within the meaning of
the Act will have the same rights to contribution as the Placement Agent, and each person, if any, who controls the Company within
the meaning of the Act will have the same rights to contribution as the Company, subject in each case to the provisions of this
Section 9. Anything in this Section 9 to the contrary notwithstanding, no party will be liable for contribution with respect to
the settlement of any claim or action effected without its written consent. This Section 9 is intended to supersede, to the extent
permitted by law, any right to contribution under the Act, the Exchange Act or otherwise available.

 

    	26

    	 

    

  

10.         Termination.

 

(a)          The
Offering may be terminated by the Placement Agent at any time prior to the expiration of the Offering Period in the event that:
(i) any of the representations, warranties or covenants of JBT contained herein or in the Memorandum shall prove to have been
false or misleading in any material respect when actually made; (ii) JBT shall have failed to perform any of its material obligations
hereunder or under any other JBT Transaction Document, Issuer Transaction Document or any other transaction document; (iii) there
shall occur any event, within the control of JBT that could materially adversely affect the transactions contemplated hereunder
or the ability of JBT to perform hereunder; or (iv) the Placement Agent determines that it is reasonably likely that any of the
conditions to Closing set forth herein will not, or cannot, be satisfied. In the event of any such termination by the Placement
Agent pursuant to clauses (i), (ii) or (iii) of this Section 10(a), the Placement Agent shall be entitled to receive from JBT,
within five (5) business days of the Termination Date, in addition to other rights and remedies it may have hereunder, at law
or otherwise, an amount equal to the sum of $100,000, which amount shall be offset by the $25,000 JBT advanced to legal counsel
for the Placement Agent (collectively, the “Termination Amount”) and the provisions of Section 3(d) shall survive
in full force and effect. In the event of a termination by the Placement Agent under Section 10(a)(iv),
the Placement Agent shall not be entitled to any further compensation pursuant to these termination provisions, except
that the provisions of Section 3(d) shall survive in full force and effect.

 

(b)          This
Offering may be terminated by JBT at any time prior to the expiration of the Offering Period (i) in the event that the Placement
Agent shall have failed to perform any of its material obligations hereunder or (ii) on account of the Placement Agent’s
fraud, illegal or willful misconduct or gross negligence. In the event of any such termination pursuant to this Section 10(b),
the Placement Agent shall not be entitled to any further compensation pursuant to these termination provisions and Sections 3(e)
– (h) shall also terminate.

 

(c)          In
the event JBT unilaterally decides for any reason (other than pursuant to Section 10(b) above or Section 10(d) below) to terminate
the Offering at any time prior to the First Closing (the “Unilateral Termination”), the Placement Agent shall
be entitled to receive from JBT $100,000 plus the Placement Agent’s out-of-pocket legal expenses not to exceed $50,000
in connection with the Offering (the “Unilateral Termination
Amount”). In addition, if within twelve (12) months after the Unilateral Termination, JBT conducts a public or private
offering of its securities or enters into a letter of intent with respect to the foregoing, then upon the closing of any such transaction,
the terminating party shall pay the Placement Agent in cash, within five (5) business days of the closing of any such transaction
an amount equal to 2% of the gross proceeds from such private or public offering (the “Additional Unilateral Termination
Amount”), provided that such percentage shall be the applicable percentages set forth in section 3(d) hereto with respect
to any gross proceeds from Tail Investors. 

 

(d)          This
Offering may be terminated upon mutual agreement of Issuer, JBT and the Placement Agent at any time prior to the expiration of
the Offering Period. In addition, upon the expiration of the Offering Period, the Offering shall terminate without any further
action of the parties hereto. If the Offering is terminated pursuant to this Section 10(d), then in cases in which no Closing
had been theretofore consummated, each party shall pay its own respective expenses. 

 

    	27

    	 

    

  

(e)          Before
any termination by the Placement Agent under Section 10(a) or by JBT under Section 10(b) shall become effective, the terminating
party shall give written notice to the other party of its intention to terminate the Offering, which shall set forth the specific
grounds for the proposed termination (the “Termination Notice”). If the specified grounds for termination, or
their resulting adverse effect on the transactions contemplated hereby, are curable, then the other party shall have ten (10) days
from the Termination Notice within which to remove such grounds or to eliminate all of their material adverse effects on the transactions
contemplated hereby; otherwise, the Offering shall terminate.

 

(f)           In
the event that a majority of the JBT capital stock or assets is sold, or JBT is merged with or merges with or into another entity
or otherwise combined with or acquired, or enters into a letter of intent or memorandum of understanding with respect to any of
the foregoing, within one year following a Unilateral Termination, then upon the closing of any such transaction, JBT or its successor
shall pay the Placement Agent in cash, within five (5) business days of the closing of any such transaction, an amount equal to
2% of the total consideration received or receivable by JBT or any of its officers, directors or stockholders in connection with
such transaction (the “Transaction Fee”). Notwithstanding the foregoing, however, if an event or transaction
shall occur that would entitle the Placement Agent to receive both the Unilateral Termination Amount and the Transaction Fee, then
the Placement Agent may elect which of the two such fees, but may elect only one of such fees, it shall collect from JBT or its
successor. In the event that the Placement Agent has elected to receive the Unilateral Termination Amount in accordance with this
Section 10, and subsequently an event or transaction occurs that would have entitled the Placement Agent to receive a Transaction
Fee in excess of such Unilateral Termination Amount, then the Placement Agent may require JBT to pay it the difference between
the Unilateral Termination Amount already paid and the amount of the Transaction Fee to which it otherwise would have been entitled
to receive from JBT.

 

(g)          Upon
any termination pursuant to this Section 10, the Placement Agent and the Company will instruct Escrow Agent to cause all monies
received with respect to the subscriptions for Units not accepted by the Company to be promptly returned to such subscribers without
interest, penalty or deduction.

 

11.         Survival.

 

(a)          The
obligations of the parties to pay any costs and expenses hereunder and to provide indemnification and contribution as provided
herein shall survive any termination hereunder. In addition, the provisions of Sections 3(d), and 8 through 16 shall survive the
sale of the Units or any termination of the Offering hereunder.

 

(b)          The
respective indemnities, covenants, representations, warranties and other statements of Issuer, JBT and the Placement Agent set
forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on
behalf of, and regardless of any access to information by, Issuer, JBT or the Placement Agent, or any of their officers or directors
or any controlling person thereof, and will survive the sale of the Units or any termination of the Offering hereunder for a period
of four years from the earlier to occur of the Final Closing or the termination of the Offering.

    	28

    	 

    

  

12.         Notices.
All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given
or made as of the date delivered personally, or the date mailed if mailed by registered or certified mail (postage prepaid, return
receipt requested) to the parties at the following addresses (or at such other address for a party as shall be specified by like
changes of address which shall be effective upon receipt) or sent by facsimile transmission, with confirmation received, if sent
to the Placement Agent, will be mailed, delivered or telefaxed and confirmed to Aegis Capital Corp., 810 Seventh Ave, 11th Floor,
New York, New York 10019, Attention: Adam K. Stern, telefax number (646) 390-9122, with a copy (which shall not constitute notice)
to: Littman Krooks LLP, 655 Third Avenue, 20th floor New York, NY 10017 Attention: Steven D. Uslaner, Esq., telefax
number (212) 490-2990, if sent to JBT or the Company, will be mailed, delivered or telefaxed and confirmed to JB Therapeutics,
Inc., One Kendall Square, Bldg 200, Cambridge, MA 02139, Attn: Yuval Cohen, CEO, with a copy (which shall not constitute notice)
to: Lowenstein Sandler LLP, 1251 Avenue of the Americas, New York, NY 10020, Attn: Steven M. Skolnick, Esq., telefax number (973)
597 2477, and if sent to Issuer, will be mailed, delivered or telefaxed and confirmed to Corbus Pharmaceuticals Holdings, Inc.,
142 West 57th St. Suite 4A, New York, NY 10019, Attn: David Hochman,
President, with a copy (which shall not constitute notice) to: Meister Selig & Fein LLP, Two Grand Central Tower, 140 East
45th Street, 19th Floor, New York, NY 10017, Attn: Kenneth S. Goodwin, Esq., provided, however, that from
and after the First Closing, notices to Issuer shall be sent in the same manner, and to the same address, as notices to JBT, with
a copy (which shall not constitute notice) to: Lowenstein Sandler LLP, 1251 Avenue of the Americas, New York, NY 10020, Attn: Steven
M. Skolnick, Esq., telefax number (973) 597 2477.

 

13.         Governing
Law, Jurisdiction. This Agreement shall be deemed to have been made and delivered in New York City and shall be governed as
to validity, interpretation, construction, affect and in all other respects by the internal laws of the State of New York. THE
PARTIES AGREE THAT ANY DISPUTE, CLAIM OR CONTROVERSY DIRECTLY OR INDIRECTLY RELATING TO OR ARISING OUT OF THIS AGREEMENT,
THE TERMINATION OR VALIDITY HEREOF, ANY ALLEGED BREACH OF THIS AGREEMENT OR THE ENGAGEMENT CONTEMPLATED HEREBY (ANY OF THE FOREGOING,
A “CLAIM”) SHALL BE SUBMITTED TO THE JUDICIAL ARBITRATION AND MEDIATION SERVICES, INC (“JAMS”), OR ITS
SUCCESSOR, IN NEW YORK, FOR FINAL AND BINDING ARBITRATION IN FRONT OF A PANEL OF THREE ARBITRATORS WITH JAMS IN NEW YORK, NEW YORK
UNDER THE JAMS COMPREHENSIVE ARBITRATION RULES AND PROCEDURES (WITH EACH OF THE SELLING AGENT AND THE COMPANY CHOOSING ONE ARBITRATOR,
AND THE CHOSEN ARBITRATORS CHOOSING THE THIRD ARBITRATOR).  THE ARBITRATORS SHALL, IN THEIR AWARD, ALLOCATE ALL OF THE COSTS
OF THE ARBITRATION, INCLUDING THE FEES OF THE ARBITRATORS AND THE REASONABLE ATTORNEYS’ FEES OF THE PREVAILING PARTY, AGAINST
THE PARTY WHO DID NOT PREVAIL.  THE AWARD IN THE ARBITRATION SHALL BE FINAL AND BINDING.  THE ARBITRATION SHALL BE GOVERNED
BY THE FEDERAL ARBITRATION ACT, 9 U.S.C. SEC. 1-16, AND THE JUDGMENT UPON THE AWARD RENDERED BY THE ARBITRATORS MAY BE ENTERED
BY ANY COURT HAVING JURISDICTION THEREOF.  THE COMPANY AND THE PLACEMENT AGENT AGREE AND CONSENT TO PERSONAL JURISDICTION,
SERVICE OF PROCESS AND VENUE IN ANY FEDERAL OR STATE COURT WITHIN THE STATE AND COUNTY OF NEW YORK IN CONNECTION WITH ANY ACTION
BROUGHT TO ENFORCE AN AWARD IN ARBITRATION.

 

    	29

    	 

    

  

14.         Miscellaneous.
No provision of this Agreement may be changed or terminated except by a writing signed by the party or parties to be charged therewith.
Unless expressly so provided, no party to this Agreement will be liable for the performance of any other party’s obligations
hereunder. Either party hereto may waive compliance by the other with any of the terms, provisions and conditions set forth herein;
provided, however, that any such waiver shall be in writing specifically setting forth those provisions waived thereby. No such
waiver shall be deemed to constitute or imply waiver of any other term, provision or condition of this Agreement. Neither party
may assign its rights or obligations under this Agreement to any other person or entity without the prior written consent of the
other party.

 

15.         Entire
Agreement; Severability. This Agreement together with any other agreement referred to herein supersedes all prior understandings
and written or oral agreements between the parties with respect to the Offering and the subject matter hereof. If any portion of
this Agreement shall be held invalid or unenforceable, then so far as is reasonable and possible (i) the remainder of this Agreement
shall be considered valid and enforceable and (ii) effect shall be given to the intent manifested by the portion held invalid or
unenforceable.

 

16.         Counterparts.
This Agreement may be executed in multiple counterparts, each of which may be executed by less than all of the parties and shall
be deemed to be an original instrument which shall be enforceable against the parties actually executing such counterparts and
all of which together shall constitute one and the same instrument. The exchange of copies of this Agreement and of signature pages
by facsimile transmission shall constitute effective execution and delivery of this Agreement as to the parties and may be used
in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile shall be deemed to be their
original signatures for all purposes.

 

[Signatures on following page.] 

 

    	30

    	 

    

 

If the foregoing is
in accordance with your understanding of the agreement among Issuer, JBT and the Placement Agent, kindly sign and return this Agreement,
whereupon it will become a binding agreement among Issuer, JBT and the Placement Agent in accordance with its terms.

 

	JB THERAPEUTICS, INC.	 
	 	 
	By:	 	 
	 	Name: Yuval Cohen	 
	 	Title:   Chief Executive Officer 	 
	 	 	 
	CORBUS PHARMACEUTICALS HOLDINGS, INC.	 
	 	 
	By:	 	 
	 	Name: David Hochman	 
	 	Title:   President	 

 

Accepted and agreed to this

__ day of March, 2014:

 

	AEGIS CAPITAL CORP. 	 
	 	 
	By: 	 	 
	 	Name:	 
	 	Title:	 

 

    	 

    	 

    

  

Exhibit A

 

Sunrise Obligation Investors

 

[attached]

 

    	 

    	 

    

  

Exhibit B-1

 

Form of Opinion-JBT Counsel

 

2.1           JB
Therapeutics, Inc. (the term "Company" when used herein, refers to JB Therapeutics, Inc.) has been duly organized as
a corporation and is validly existing and in good standing under the laws of the jurisdiction of its incorporation, has full corporate
power and authority to own, lease and operate its properties and conduct its business as described in the Memorandum and is duly
qualified as a foreign corporation for the transaction of business and is in good standing in each jurisdiction where the conduct
of its business makes such qualification necessary, except where the failure to so qualify would not have a material adverse effect
upon the business (as currently conducted), financial condition, prospects or results of operation of the Company (a "Material
Adverse Effect").

 

2.2           The
authorized capital stock of the Company on the date hereof consists of [INSERT CAPITALIZATION] (i) ________ shares of Common Stock,
$0.0001 par value per share, and (ii) ___________ shares of Preferred Stock, $0.0001 par value per share, all of which have been
designated as Series A Preferred Stock.

 

2.3           The
execution and delivery by the Company of the Transaction Documents to which it is a party and the consummation by the Company of
the transactions contemplated thereby have been duly authorized by all necessary corporate action on the part of the Company and
duly executed and delivered by the Company. Each of the Transaction Documents to which it is a party constitutes the legal, valid
and binding obligation of the Company, enforceable against the Company in accordance with its terms.

 

2.4           The
execution and delivery by the Company of the Transaction Documents2 to which it is a party and the consummation by the
Company of the transactions contemplated thereby will not (i) violate the provisions of the Delaware General Corporation Law or
any United States federal or state law, rule or regulation known to us to be currently applicable to the Company or (ii) violate
the provisions of the Company's Certificate of Incorporation or By-Laws; (iii) violate any judgment, decree, order or award known
to us of any court, governmental body or arbitrator having jurisdiction over the Company; or (iv) result in the breach or termination
of any material term or provision of an agreement known to us to which the Company is a party, except in the case of clauses (i),
(iii) and (iv) where the breach or violation would not have a Material Adverse Effect on the Company or its ability to perform
its obligations under the Transaction Documents.

 

 

2 Transaction Documents should include
the Placement Agency Agreement, Escrow Deposit Agreement, the Merger Agreement, Warrant, Placement Agent Warrant; Registration
Rights Agreement and Subscription Agreements.

 

    	 

    	 

    

  

2.5           To
our knowledge, there is no action, proceeding or litigation pending or threatened against the Company before any court, governmental
or administrative agency or body that would materially adversely affect the Company’s ability to consummate the transactions
contemplated by the Transaction Documents.

 

2.6           Assuming
that the Shares and Warrants were sold only to "accredited investors" (as defined in Rule 501 of Regulation D promulgated
under the Securities Act of 1933, as amended ("1933 Act")) and the Placement Agent complied in all material respects
with Regulation D and the terms and conditions of the Offering set forth in the Placement Agency Agreement and the Memorandum,
such sales were made in conformity in all material respects with the requirements of Section 4(a)(2) of the 1933 Act and Regulation
D, and with the requirements of all other United States federal regulations applicable to the Company currently in effect relating
to private offerings of securities of the type made in the Offering.

 

2.7           Either
(i) no consent, approval or authorization of, or other action by, and no notice to or filing with, any United States federal or
state governmental authority on the part of the Company is required in connection with the valid execution and delivery of the
Transaction Documents to which it is a party and the consummation by the Company of the transactions contemplated thereunder, except
for (A) the filing of a Form D that may be filed with the United States Securities and Exchange Commission; (B) any filings under
the securities laws of the various jurisdictions in which the Shares, Warrants and Placement Agent Warrants are being offered and
sold in the Offering; and (C) any filings relating to public disclosure of the transactions contemplated by the Transaction Documents,
or (ii) any required consent, approval, authorization, action or filing has been obtained, performed or made by the Company.

 

    	 

    	 

    

  

Exhibit B-2

Form of Opinion-Issuer Counsel

 

2.1           Based
solely upon the Certificate of Good Standing, the Company is a corporation duly incorporated, validly existing and in good standing
under the laws of the State of Delaware.

 

2.2           The
authorized capital stock of the Company on the date hereof consists of 150,000,000 shares of common stock, $0.0001 par value per
share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. All outstanding shares of capital stock of the Company
have been duly authorized and are validly issued, fully paid and non-assessable

 

2.3           The
shares of Common Stock issued in connection with the Merger and in connection with the Offering (the “Shares”), the
Merger Warrants, the Investor Warrants, the Placement Agent Warrants, and the shares of Common Stock issuable upon exercise of
the Merger Warrants, the Investor Warrants and the Placement Agent Warrants have been duly authorized for issuance by all necessary
corporate action on the part of the Company. The Shares and the shares of Common Stock issuable upon exercise of the Merger Warrants,
Investor Warrants and the Placement Agent Warrants when issued, sold and delivered against payment therefore in accordance with
the provisions of the Memorandum, the Subscription Agreements, the Warrants or the Placement Agent Warrants, as applicable, will
be duly and validly issued, fully paid and non-assessable. The issuance of the Shares, the Investor Warrants, the Merger Warrants
and the Placement Agent Warrants and the shares of Common Stock issuable upon exercise of the Warrants and the Placement Agent
Warrants are not subject to any statutory or, to our knowledge, contractual or other preemptive rights under any agreement. A sufficient
number of authorized but unissued shares of Common Stock have been reserved for issuance upon exercise of the Investor Warrants,
the Merger Warrants and the Placement Agent Warrants.

 

2.4           The
execution and delivery by the Company of the Transaction Documents to which they are a party and the consummation by the Company
of the transactions contemplated thereby have been duly authorized by all necessary corporate action on the part of the Company,
and duly executed and delivered by the Company, as applicable. Each of the Transaction Documents to which it is a party constitutes
the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.

 

2.5           The
execution and delivery by the Company of the Transaction Documents3 to which they are a party and the consummation by
the Company of the transactions contemplated thereby will not (i) violate the provisions of the Delaware General Corporation Law
or any United States federal or state law, rule or regulation known to us to be currently applicable to the Company, (ii) violate
the provisions of the Company's Certificate of Incorporation or By-Laws; (iii) violate any judgment, decree, order or award known
to us of any court, governmental body or arbitrator having jurisdiction over the Company; or (iv) result in the breach or termination
of any material term or provision of an agreement known to us to which the Company is a party, except in the case of clauses (i),
(iii) or (iv) where the breach or violation would not have a Material Adverse Effect on the Company or its ability to perform its
obligations under the Transaction Documents.

 

 

3 Transaction Documents should include
the Placement Agency Agreement, Escrow Deposit Agreement, the Merger Agreement, Merger Warrant, Investor Warrant, Placement Agent
Warrant; Registration Rights Agreement and Subscription Agreements.

 

    	 

    	 

    

  

2.6           To
our knowledge, there is no action, proceeding or litigation pending or threatened against the Company before any court, governmental
or administrative agency or body that would materially adversely affect the Company’s ability to consummate the transactions
contemplated by the Transaction Documents.

 

2.7           Either
(i) no consent, approval or authorization of, or other action by, and no notice to or filing with, any United States federal or
state governmental authority on the part of the Company is required in connection with the valid execution and delivery of the
Transaction Documents to which it is a party and the consummation by the Company of the transactions contemplated thereunder, except
for (A) the filing of a Form D that may be filed with the United States Securities and Exchange Commission; (B) any filings under
the securities laws of the various jurisdictions in which the Shares, the Investor Warrants, the Merger Warrants and Placement
Agent Warrants are being offered and sold in the Offering; and (C) any filings relating to public disclosure of the transactions
contemplated by the Transaction Documents, or (ii) any required consent, approval, authorization, action or filing has been obtained,
performed or made by the Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]